PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 19085111-11 2008 Results showed that the maximum permissible cosolvent concentrations for hASBT uptake studies, without compromising assay results or causing cytotoxicity, are 1% DMAC, 1% DMF, 2.5% DMSO, 2.5% methanol, and 2.5% ethanol. dimethylacetamide 162-166 solute carrier family 10 member 2 Homo sapiens 73-78 19085111-12 2008 Additionally, both NaOH-free, acetonitrile-based cell lysis methods provided similar recovery and hASBT results, compared to NaOH method. acetonitrile 30-42 solute carrier family 10 member 2 Homo sapiens 98-103 18508772-0 2008 Conserved aspartic acid residues lining the extracellular loop 1 of sodium-coupled bile acid transporter ASBT Interact with Na+ and 7alpha-OH moieties on the ligand cholestane skeleton. Aspartic Acid 10-23 solute carrier family 10 member 2 Homo sapiens 105-109 18508772-0 2008 Conserved aspartic acid residues lining the extracellular loop 1 of sodium-coupled bile acid transporter ASBT Interact with Na+ and 7alpha-OH moieties on the ligand cholestane skeleton. 7alpha-oh 132-141 solute carrier family 10 member 2 Homo sapiens 105-109 18508772-0 2008 Conserved aspartic acid residues lining the extracellular loop 1 of sodium-coupled bile acid transporter ASBT Interact with Na+ and 7alpha-OH moieties on the ligand cholestane skeleton. Cholestanes 165-175 solute carrier family 10 member 2 Homo sapiens 105-109 18668439-3 2008 In the ileum, absorption of bile acids from the lumen into epithelial cells is mediated by the apical Na(+) bile salt transporter (ASBT), whereas exit into portal blood across the basolateral membrane is mediated by the organic solute transporter alpha/beta (OSTalpha/beta) heterodimer. Bile Acids and Salts 28-38 solute carrier family 10 member 2 Homo sapiens 131-135 18311924-1 2008 We report the involvement of transmembrane domain 4 (TM4) of hASBT in forming the putative translocation pathway, using cysteine-scanning mutagenesis in conjunction with solvent-accessibility studies using the membrane-impermeant, sulfhydryl-specific methanethiosulfonate reagents. Cysteine 120-128 solute carrier family 10 member 2 Homo sapiens 61-66 18028035-1 2008 The hASBT (human apical Na(+)-dependent bile acid transporter) constitutes a key target of anti-hypercholesterolaemic therapies and pro-drug approaches; physiologically, hASBT actively reclaims bile acids along the terminal ileum via Na(+) co-transport. Bile Acids and Salts 194-204 solute carrier family 10 member 2 Homo sapiens 4-9 18028035-1 2008 The hASBT (human apical Na(+)-dependent bile acid transporter) constitutes a key target of anti-hypercholesterolaemic therapies and pro-drug approaches; physiologically, hASBT actively reclaims bile acids along the terminal ileum via Na(+) co-transport. Bile Acids and Salts 194-204 solute carrier family 10 member 2 Homo sapiens 170-175 18311924-1 2008 We report the involvement of transmembrane domain 4 (TM4) of hASBT in forming the putative translocation pathway, using cysteine-scanning mutagenesis in conjunction with solvent-accessibility studies using the membrane-impermeant, sulfhydryl-specific methanethiosulfonate reagents. Sulfhydryl Compounds 231-241 solute carrier family 10 member 2 Homo sapiens 61-66 18311924-1 2008 We report the involvement of transmembrane domain 4 (TM4) of hASBT in forming the putative translocation pathway, using cysteine-scanning mutagenesis in conjunction with solvent-accessibility studies using the membrane-impermeant, sulfhydryl-specific methanethiosulfonate reagents. methanethiosulfonate 251-271 solute carrier family 10 member 2 Homo sapiens 61-66 18311924-2 2008 We individually mutated each of the 21 amino acids in TM4 to cysteine on a fully functional, MTS-resistant C270A-hASBT template. Cysteine 61-69 solute carrier family 10 member 2 Homo sapiens 113-118 18063707-8 2008 Our study illustrates that cholesterol content of lipid rafts is essential for the optimal activity of ASBT and support the association of ASBT with lipid rafts. Cholesterol 27-38 solute carrier family 10 member 2 Homo sapiens 139-143 18063707-9 2008 These findings suggest a novel mechanism by which ASBT activity may be rapidly modulated by alterations in cholesterol content of plasma membrane and thus have important implications in processes related to maintenance of bile acid and cholesterol homeostasis. Cholesterol 107-118 solute carrier family 10 member 2 Homo sapiens 50-54 18063707-9 2008 These findings suggest a novel mechanism by which ASBT activity may be rapidly modulated by alterations in cholesterol content of plasma membrane and thus have important implications in processes related to maintenance of bile acid and cholesterol homeostasis. Bile Acids and Salts 222-231 solute carrier family 10 member 2 Homo sapiens 50-54 18063707-9 2008 These findings suggest a novel mechanism by which ASBT activity may be rapidly modulated by alterations in cholesterol content of plasma membrane and thus have important implications in processes related to maintenance of bile acid and cholesterol homeostasis. Cholesterol 236-247 solute carrier family 10 member 2 Homo sapiens 50-54 17171805-2 2006 In this study, a Swedish family with bile acid malabsorption in three consecutive generations was screened for mutations in the ileal apical sodium-bile acid cotransporter gene (ASBT; gene symbol, SLC10A2) and in the genes for several of the nuclear receptors known to be important for ASBT expression: the farnesoid X receptor (FXR) and peroxisome proliferator activated receptor alpha (PPARalpha). Bile Acids and Salts 37-46 solute carrier family 10 member 2 Homo sapiens 178-182 17404808-7 2007 Intestinal epithelial cells reabsorb the majority of the secreted bile acids through the apical sodium dependent bile acid transporter (ASBT) and sodium independent organic anion transporting peptide (OATPs). Bile Acids and Salts 66-76 solute carrier family 10 member 2 Homo sapiens 89-134 17404808-7 2007 Intestinal epithelial cells reabsorb the majority of the secreted bile acids through the apical sodium dependent bile acid transporter (ASBT) and sodium independent organic anion transporting peptide (OATPs). Bile Acids and Salts 66-76 solute carrier family 10 member 2 Homo sapiens 136-140 17038509-2 2007 Taurocholate flux was measured across human apical sodium-dependent bile acid transporter (hASBT)-Madin-Darby canine kidney monolayers on different occasions and kinetic parameters estimated with and without considering ABL. Taurocholic Acid 0-12 solute carrier family 10 member 2 Homo sapiens 91-96 18063707-0 2008 Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts. Cholesterol 90-101 solute carrier family 10 member 2 Homo sapiens 43-47 18063707-1 2008 Apical sodium-dependent bile acid transporter (ASBT) represents a highly efficient conservation mechanism of bile acids via mediation of their active transport across the luminal membrane of terminal ileum. Bile Acids and Salts 109-119 solute carrier family 10 member 2 Homo sapiens 0-45 18063707-1 2008 Apical sodium-dependent bile acid transporter (ASBT) represents a highly efficient conservation mechanism of bile acids via mediation of their active transport across the luminal membrane of terminal ileum. Bile Acids and Salts 109-119 solute carrier family 10 member 2 Homo sapiens 47-51 18063707-2 2008 To gain insight into the cellular regulation of ASBT, we investigated the association of ASBT with cholesterol and sphingolipid-enriched specialized plasma membrane microdomains known as lipid rafts and examined the role of membrane cholesterol in maintaining ASBT function. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 89-93 18063707-2 2008 To gain insight into the cellular regulation of ASBT, we investigated the association of ASBT with cholesterol and sphingolipid-enriched specialized plasma membrane microdomains known as lipid rafts and examined the role of membrane cholesterol in maintaining ASBT function. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 89-93 18063707-5 2008 Disruption of lipid rafts by depletion of membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the association of ASBT with lipid rafts, which was paralleled by a decrease in ASBT activity in Caco-2 and HEK-293 cells treated with MbetaCD. Cholesterol 51-62 solute carrier family 10 member 2 Homo sapiens 144-148 18063707-5 2008 Disruption of lipid rafts by depletion of membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the association of ASBT with lipid rafts, which was paralleled by a decrease in ASBT activity in Caco-2 and HEK-293 cells treated with MbetaCD. methyl-beta-cyclodextrin 68-92 solute carrier family 10 member 2 Homo sapiens 144-148 18063707-5 2008 Disruption of lipid rafts by depletion of membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the association of ASBT with lipid rafts, which was paralleled by a decrease in ASBT activity in Caco-2 and HEK-293 cells treated with MbetaCD. methyl-beta-cyclodextrin 68-92 solute carrier family 10 member 2 Homo sapiens 205-209 18063707-5 2008 Disruption of lipid rafts by depletion of membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the association of ASBT with lipid rafts, which was paralleled by a decrease in ASBT activity in Caco-2 and HEK-293 cells treated with MbetaCD. methyl-beta-cyclodextrin 94-101 solute carrier family 10 member 2 Homo sapiens 144-148 18063707-5 2008 Disruption of lipid rafts by depletion of membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the association of ASBT with lipid rafts, which was paralleled by a decrease in ASBT activity in Caco-2 and HEK-293 cells treated with MbetaCD. methyl-beta-cyclodextrin 94-101 solute carrier family 10 member 2 Homo sapiens 205-209 18063707-5 2008 Disruption of lipid rafts by depletion of membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the association of ASBT with lipid rafts, which was paralleled by a decrease in ASBT activity in Caco-2 and HEK-293 cells treated with MbetaCD. methyl-beta-cyclodextrin 260-267 solute carrier family 10 member 2 Homo sapiens 144-148 18063707-6 2008 The inhibition in ASBT activity by MbetaCD was blocked in the cells treated with MbetaCD-cholesterol complexes. methyl-beta-cyclodextrin 35-42 solute carrier family 10 member 2 Homo sapiens 18-22 18063707-8 2008 Our study illustrates that cholesterol content of lipid rafts is essential for the optimal activity of ASBT and support the association of ASBT with lipid rafts. Cholesterol 27-38 solute carrier family 10 member 2 Homo sapiens 103-107 17964214-1 2007 Using a luciferase reporter assay in both LMH cells and Caco2 cells we found that certain bile acids including unconjugated deoxycholic and others transactivated the ileal apical sodium-dependent bile acid transporter (ASBT) at concentrations ranging from 20 to 300 microM. Bile Acids and Salts 90-100 solute carrier family 10 member 2 Homo sapiens 219-223 17964214-2 2007 Confirming this effect, addition of deoxycholic acid to fresh human ileal biopsies caused an approximate 40% increase in endogenous ASBT mRNA production. Deoxycholic Acid 36-52 solute carrier family 10 member 2 Homo sapiens 132-136 17964214-7 2007 These studies demonstrate that certain bile acids stimulate ASBT gene expression acting on the down-stream AP-1 response element via the EGF receptor and MEK cascade. Bile Acids and Salts 39-49 solute carrier family 10 member 2 Homo sapiens 60-64 17931197-6 2007 In addition,bile acids have been shown to enter cholangiocytes through the apical, Na(+)-dependent bile acid transporter, ASBT, which has a marked impact on cholangiocyte pathobiology. Bile Acids and Salts 12-22 solute carrier family 10 member 2 Homo sapiens 122-126 17685606-2 2007 The crystal structure of Mg2Rh0.75(1)B6.50(4) is determined using single-crystal X-ray diffraction, electron diffraction, and high-resolution electron microscopy (space group Pbam, a=8.795(2) A, b=11.060(2) A, c=3.5279(5) A, Z=4, 630 reflections, RF=0.045). mg2rh0 25-31 solute carrier family 10 member 2 Homo sapiens 175-179 16934605-8 2006 To confirm the presence of ileal bile acid transporter (IBAT) gene message and function, we measured sodium-dependent bile acid uptake and IBAT-messenger RNA. Sodium 101-107 solute carrier family 10 member 2 Homo sapiens 56-60 16934605-8 2006 To confirm the presence of ileal bile acid transporter (IBAT) gene message and function, we measured sodium-dependent bile acid uptake and IBAT-messenger RNA. Bile Acids and Salts 33-42 solute carrier family 10 member 2 Homo sapiens 56-60 16697742-11 2006 Remarkably, NTCP*2, a variant known to have a near complete loss of function for bile acids, exhibited a profound gain of function for rosuvastatin. Bile Acids and Salts 81-91 solute carrier family 10 member 2 Homo sapiens 12-18 16773712-2 2006 A selective transporter for bile acids, the Apical Sodium Bile Acid Cotransporter (ASBT) (also referred to as Ibat; gene name Slc10a2) is localized on the cholangiocyte apical membrane. Bile Acids and Salts 28-38 solute carrier family 10 member 2 Homo sapiens 44-81 16773712-2 2006 A selective transporter for bile acids, the Apical Sodium Bile Acid Cotransporter (ASBT) (also referred to as Ibat; gene name Slc10a2) is localized on the cholangiocyte apical membrane. Bile Acids and Salts 28-38 solute carrier family 10 member 2 Homo sapiens 83-87 16773712-2 2006 A selective transporter for bile acids, the Apical Sodium Bile Acid Cotransporter (ASBT) (also referred to as Ibat; gene name Slc10a2) is localized on the cholangiocyte apical membrane. Bile Acids and Salts 28-38 solute carrier family 10 member 2 Homo sapiens 110-114 16773712-2 2006 A selective transporter for bile acids, the Apical Sodium Bile Acid Cotransporter (ASBT) (also referred to as Ibat; gene name Slc10a2) is localized on the cholangiocyte apical membrane. Bile Acids and Salts 28-38 solute carrier family 10 member 2 Homo sapiens 126-133 16773712-9 2006 ASBT is chronically regulated by changes in gene expression in response to biliary bile acid concentration and inflammatory cytokines. Bile Acids and Salts 83-92 solute carrier family 10 member 2 Homo sapiens 0-4 16773712-10 2006 Another potential function of cholangiocyte ASBT is to allow cholangiocytes to sample biliary bile acids in order to activate intracellular signaling pathways. Bile Acids and Salts 94-104 solute carrier family 10 member 2 Homo sapiens 44-48 16687134-7 2006 Potent non-systemic ASBT inhibitor R-146224 decreases bile acid reabsorption by inhibiting the ileal bile acid active transport system, resulting in hypolipidemic activity. 1-(7-((1-(3,5-diethoxyphenyl)-3-(((3,5-difluorophenyl)(ethyl)amino)carbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)oxy)heptyl)-1-methylpiperidinium bromide 35-43 solute carrier family 10 member 2 Homo sapiens 20-24 16687134-7 2006 Potent non-systemic ASBT inhibitor R-146224 decreases bile acid reabsorption by inhibiting the ileal bile acid active transport system, resulting in hypolipidemic activity. Bile Acids and Salts 54-63 solute carrier family 10 member 2 Homo sapiens 20-24 16687134-7 2006 Potent non-systemic ASBT inhibitor R-146224 decreases bile acid reabsorption by inhibiting the ileal bile acid active transport system, resulting in hypolipidemic activity. Bile Acids and Salts 101-110 solute carrier family 10 member 2 Homo sapiens 20-24 16484503-0 2006 Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Cholesterol 0-11 solute carrier family 10 member 2 Homo sapiens 56-101 16484503-0 2006 Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Cholesterol 0-11 solute carrier family 10 member 2 Homo sapiens 103-107 16823213-1 2006 In the title salt, also known as pentane-1,5-diammonium dichloride, C(5)H(16)N(2)(2+)x2Cl(-), the cation exists in an ideal fully extended conformation and lies on a mirror plane in the space group Pbam. Salts 13-17 solute carrier family 10 member 2 Homo sapiens 198-202 16823213-1 2006 In the title salt, also known as pentane-1,5-diammonium dichloride, C(5)H(16)N(2)(2+)x2Cl(-), the cation exists in an ideal fully extended conformation and lies on a mirror plane in the space group Pbam. pentane-1,5-diammonium dichloride 33-66 solute carrier family 10 member 2 Homo sapiens 198-202 16823213-1 2006 In the title salt, also known as pentane-1,5-diammonium dichloride, C(5)H(16)N(2)(2+)x2Cl(-), the cation exists in an ideal fully extended conformation and lies on a mirror plane in the space group Pbam. c(5)h(16)n(2)(2+)x2cl 68-89 solute carrier family 10 member 2 Homo sapiens 198-202 16783481-0 2006 Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Bile Acids and Salts 22-32 solute carrier family 10 member 2 Homo sapiens 91-96 16783481-2 2006 The objective of this study was to characterize hASBT interaction with its native substrates, bile acids, and to evaluate C-24 conjugation and steroidal hydroxylation on transport affinity and inhibition potency. Bile Acids and Salts 94-104 solute carrier family 10 member 2 Homo sapiens 48-53 16783481-9 2006 Conjugated dihydroxy and monohydroxy bile acids exhibited the highest hASBT-mediated transport (i.e., lower Kt and higher Jmax). dihydroxy and monohydroxy bile acids 11-47 solute carrier family 10 member 2 Homo sapiens 70-75 16783481-12 2006 CONCLUSION: C-24 conjugation and steroidal hydroxylation pattern modulated native bile acid interaction with hASBT, with C-24 effect dominating steroidal hydroxylation effect. Bile Acids and Salts 82-91 solute carrier family 10 member 2 Homo sapiens 109-114 16783481-13 2006 Results indicate that bile acid binding to hASBT may be the rate-limiting step in the apical transport of bile acids. Bile Acids and Salts 22-31 solute carrier family 10 member 2 Homo sapiens 43-48 16783481-13 2006 Results indicate that bile acid binding to hASBT may be the rate-limiting step in the apical transport of bile acids. Bile Acids and Salts 106-116 solute carrier family 10 member 2 Homo sapiens 43-48 16697742-11 2006 Remarkably, NTCP*2, a variant known to have a near complete loss of function for bile acids, exhibited a profound gain of function for rosuvastatin. Rosuvastatin Calcium 135-147 solute carrier family 10 member 2 Homo sapiens 12-18 16749860-2 2006 The objective of this study was to evaluate the influence of ionic character and steric bulk in the C-24 region of bile acid conjugates in governing interaction with hASBT. Bile Acids and Salts 115-124 solute carrier family 10 member 2 Homo sapiens 166-171 16749860-13 2006 Overall, C-24 ionic character influenced interaction with hASBT. Carbon 9-10 solute carrier family 10 member 2 Homo sapiens 58-63 16237211-2 2006 A deficiency of the apical sodium bile acid transporter (ASBT) and ileal lipid binding protein (ILBP) in the small intestine may result in bile acid loss into the colon and might promote gallstone formation by reducing the bile acid pool and increasing the amount of hydrophobic bile salts. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 57-61 16150853-1 2006 BACKGROUND/AIMS: The apical sodium dependent bile acid transporter ASBT (SLC10A2) contributes substantially to the enterohepatic circulation of bile acids by their reabsorption from the intestine. Bile Acids and Salts 144-154 solute carrier family 10 member 2 Homo sapiens 67-71 16150853-1 2006 BACKGROUND/AIMS: The apical sodium dependent bile acid transporter ASBT (SLC10A2) contributes substantially to the enterohepatic circulation of bile acids by their reabsorption from the intestine. Bile Acids and Salts 144-154 solute carrier family 10 member 2 Homo sapiens 73-80 16150853-10 2006 Individual ASBT mRNA expression was inversely correlated with bile acid and bilirubin plasma concentrations. Bile Acids and Salts 62-71 solute carrier family 10 member 2 Homo sapiens 11-15 16150853-10 2006 Individual ASBT mRNA expression was inversely correlated with bile acid and bilirubin plasma concentrations. Bilirubin 76-85 solute carrier family 10 member 2 Homo sapiens 11-15 16541252-2 2006 These carriers are essentially involved in the maintenance of the enterohepatic circulation of bile acids mediating the first step of active bile acid transport through the membrane barriers in the liver (NTCP) and intestine (ASBT). Bile Acids and Salts 95-105 solute carrier family 10 member 2 Homo sapiens 226-230 16541252-2 2006 These carriers are essentially involved in the maintenance of the enterohepatic circulation of bile acids mediating the first step of active bile acid transport through the membrane barriers in the liver (NTCP) and intestine (ASBT). Bile Acids and Salts 95-104 solute carrier family 10 member 2 Homo sapiens 226-230 16541252-10 2006 Based on the high structural homology between ASBT and SOAT, pharmacological inhibitors of the ASBT, which are currently being tested in clinical trials for cholesterol-lowering therapy, should be evaluated for their cross-reactivity with SOAT. Cholesterol 157-168 solute carrier family 10 member 2 Homo sapiens 95-99 16411770-7 2006 Confocal microscopy confirmed membrane localization of epitope-tagged hASBT in saponin-treated (permeabilized) and nonpermeabilized transfected COS-1 and MDCK cells. Saponins 79-86 solute carrier family 10 member 2 Homo sapiens 70-75 16237211-2 2006 A deficiency of the apical sodium bile acid transporter (ASBT) and ileal lipid binding protein (ILBP) in the small intestine may result in bile acid loss into the colon and might promote gallstone formation by reducing the bile acid pool and increasing the amount of hydrophobic bile salts. Bile Acids and Salts 279-289 solute carrier family 10 member 2 Homo sapiens 20-55 16237211-2 2006 A deficiency of the apical sodium bile acid transporter (ASBT) and ileal lipid binding protein (ILBP) in the small intestine may result in bile acid loss into the colon and might promote gallstone formation by reducing the bile acid pool and increasing the amount of hydrophobic bile salts. Bile Acids and Salts 279-289 solute carrier family 10 member 2 Homo sapiens 57-61 16123152-2 2006 NTCP and the ileal transporter ASBT (apical sodium-dependent bile acid transporter) are two sodium-dependent transporters critical for the enterohepatic circulation of bile acids. Bile Acids and Salts 168-178 solute carrier family 10 member 2 Homo sapiens 31-35 16123152-2 2006 NTCP and the ileal transporter ASBT (apical sodium-dependent bile acid transporter) are two sodium-dependent transporters critical for the enterohepatic circulation of bile acids. Bile Acids and Salts 168-178 solute carrier family 10 member 2 Homo sapiens 37-82 16237211-2 2006 A deficiency of the apical sodium bile acid transporter (ASBT) and ileal lipid binding protein (ILBP) in the small intestine may result in bile acid loss into the colon and might promote gallstone formation by reducing the bile acid pool and increasing the amount of hydrophobic bile salts. Bile Acids and Salts 139-148 solute carrier family 10 member 2 Homo sapiens 20-55 16237211-2 2006 A deficiency of the apical sodium bile acid transporter (ASBT) and ileal lipid binding protein (ILBP) in the small intestine may result in bile acid loss into the colon and might promote gallstone formation by reducing the bile acid pool and increasing the amount of hydrophobic bile salts. Bile Acids and Salts 139-148 solute carrier family 10 member 2 Homo sapiens 57-61 16469397-1 2005 The apical sodium dependent bile acid transporter (ASBT) mediates ileal bile acid reabsorption. Bile Acids and Salts 28-37 solute carrier family 10 member 2 Homo sapiens 51-55 16469397-3 2005 Bile-acid induced negative feedback regulation of mouse (m) and human (h) ASBT occurs via LRH-1 and RAR/RXR, respectively. Bile Acids and Salts 0-9 solute carrier family 10 member 2 Homo sapiens 74-78 16469397-8 2005 siFTF reduced hASBT but not mASBT activity; siLRH reduced mASBT but not hASBT activity. siftf 0-5 solute carrier family 10 member 2 Homo sapiens 14-19 16230354-8 2005 When stable cells were transfected with an expression plasmid of the ileal bile acid transporter 14(IBAT) essential for the reabsorption of conjugated bile acids, the C-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in 14C-labeled CDCA uptake, which is independent of IBAT. Bile Acids and Salts 151-161 solute carrier family 10 member 2 Homo sapiens 100-104 16230354-8 2005 When stable cells were transfected with an expression plasmid of the ileal bile acid transporter 14(IBAT) essential for the reabsorption of conjugated bile acids, the C-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in 14C-labeled CDCA uptake, which is independent of IBAT. Bile Acids and Salts 75-84 solute carrier family 10 member 2 Homo sapiens 100-104 16230354-8 2005 When stable cells were transfected with an expression plasmid of the ileal bile acid transporter 14(IBAT) essential for the reabsorption of conjugated bile acids, the C-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in 14C-labeled CDCA uptake, which is independent of IBAT. Bile Acids and Salts 75-84 solute carrier family 10 member 2 Homo sapiens 251-255 16230354-8 2005 When stable cells were transfected with an expression plasmid of the ileal bile acid transporter 14(IBAT) essential for the reabsorption of conjugated bile acids, the C-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in 14C-labeled CDCA uptake, which is independent of IBAT. Bile Acids and Salts 75-84 solute carrier family 10 member 2 Homo sapiens 251-255 16230354-8 2005 When stable cells were transfected with an expression plasmid of the ileal bile acid transporter 14(IBAT) essential for the reabsorption of conjugated bile acids, the C-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in 14C-labeled CDCA uptake, which is independent of IBAT. Glycocholic Acid 199-215 solute carrier family 10 member 2 Homo sapiens 100-104 16230354-8 2005 When stable cells were transfected with an expression plasmid of the ileal bile acid transporter 14(IBAT) essential for the reabsorption of conjugated bile acids, the C-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in 14C-labeled CDCA uptake, which is independent of IBAT. Carbon-14 330-333 solute carrier family 10 member 2 Homo sapiens 100-104 16230354-8 2005 When stable cells were transfected with an expression plasmid of the ileal bile acid transporter 14(IBAT) essential for the reabsorption of conjugated bile acids, the C-labeled conjugated bile acid, glycocholic acid, was more efficiently imported via IBAT in the presence than absence of I-BABP, whereas no change was observed in 14C-labeled CDCA uptake, which is independent of IBAT. Chenodeoxycholic Acid 342-346 solute carrier family 10 member 2 Homo sapiens 100-104 16230354-10 2005 Taken together, the current data provide the first evidence that I-BABP is functionally associated with FXR and IBAT in the nucleus and on the membrane, respectively, stimulating FXR transcriptional activity and the conjugated bile acid uptake mediated by IBAT in the ileum. Bile Acids and Salts 227-236 solute carrier family 10 member 2 Homo sapiens 112-116 16078136-4 2005 METHODS: cDNA encoding hASBT was cloned into pcDNA3.1-V5-polyHis-B to generate an expression plasmid that was then transfected into MDCK-II cells. polyhis 57-64 solute carrier family 10 member 2 Homo sapiens 23-28 16317684-2 2005 The two subunits of the transporter were expressed together in human small intestine, kidney, and liver, tissues that also express the apical sodium-dependent bile acid uptake transporter ASBT (SLC10A2). Sodium 142-148 solute carrier family 10 member 2 Homo sapiens 188-192 16317684-2 2005 The two subunits of the transporter were expressed together in human small intestine, kidney, and liver, tissues that also express the apical sodium-dependent bile acid uptake transporter ASBT (SLC10A2). Sodium 142-148 solute carrier family 10 member 2 Homo sapiens 194-201 16317684-2 2005 The two subunits of the transporter were expressed together in human small intestine, kidney, and liver, tissues that also express the apical sodium-dependent bile acid uptake transporter ASBT (SLC10A2). Bile Acids and Salts 159-168 solute carrier family 10 member 2 Homo sapiens 188-192 16317684-2 2005 The two subunits of the transporter were expressed together in human small intestine, kidney, and liver, tissues that also express the apical sodium-dependent bile acid uptake transporter ASBT (SLC10A2). Bile Acids and Salts 159-168 solute carrier family 10 member 2 Homo sapiens 194-201 16134950-2 2005 We believe that by preventing the reabsorption of bile acids, a minimally absorbed apical sodium-codependent bile acid transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side effects of an absorbed drug. Bile Acids and Salts 50-60 solute carrier family 10 member 2 Homo sapiens 132-136 16134950-2 2005 We believe that by preventing the reabsorption of bile acids, a minimally absorbed apical sodium-codependent bile acid transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side effects of an absorbed drug. Cholesterol 170-181 solute carrier family 10 member 2 Homo sapiens 132-136 16134950-3 2005 A series of novel benzothiepines (3R,3R"-2,3,4,5-tetrahydro-5-aryl-1-benzothiepin-4-ol 1,1-dioxides) were synthesized and tested for their ability to inhibit the apical sodium dependent bile acid transport (ASBT)-mediated uptake of [(14)C]taurocholate (TC) in H14 cells. benzothiepines 18-32 solute carrier family 10 member 2 Homo sapiens 207-211 16134950-3 2005 A series of novel benzothiepines (3R,3R"-2,3,4,5-tetrahydro-5-aryl-1-benzothiepin-4-ol 1,1-dioxides) were synthesized and tested for their ability to inhibit the apical sodium dependent bile acid transport (ASBT)-mediated uptake of [(14)C]taurocholate (TC) in H14 cells. 3r,3r"-2,3,4,5-tetrahydro-5-aryl-1-benzothiepin-4-ol 34-86 solute carrier family 10 member 2 Homo sapiens 207-211 16134950-6 2005 The reported results describe the synthesis and SAR development of this benzothiepine class of ASBT inhibitors resulting in an 6000-fold improvement in ASBT inhibition with desired minimal systemic exposure of this locally acting drug candidate. 1-Benzothiepin 72-85 solute carrier family 10 member 2 Homo sapiens 95-99 16134950-6 2005 The reported results describe the synthesis and SAR development of this benzothiepine class of ASBT inhibitors resulting in an 6000-fold improvement in ASBT inhibition with desired minimal systemic exposure of this locally acting drug candidate. 1-Benzothiepin 72-85 solute carrier family 10 member 2 Homo sapiens 152-156 16134951-2 2005 Since the primary site for active bile acid reabsorption is via ASBT, which is localized on the luminal surface of the distal ileum, we reasoned that a nonsystemic inhibitor would be desirable to minimize or eliminate potential systemic side effects of an absorbed drug. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 64-68 16134951-4 2005 A series of benzothiepines were prepared to refine the structure-activity relationship of the substituted phenyl ring at the 5-position of benzothiepine ring and to identify potent, crystalline, nonhygroscopic, and efficacious ASBT inhibitors with low systemic exposure. benzothiepines 12-26 solute carrier family 10 member 2 Homo sapiens 227-231 16134951-4 2005 A series of benzothiepines were prepared to refine the structure-activity relationship of the substituted phenyl ring at the 5-position of benzothiepine ring and to identify potent, crystalline, nonhygroscopic, and efficacious ASBT inhibitors with low systemic exposure. 1-Benzothiepin 12-25 solute carrier family 10 member 2 Homo sapiens 227-231 16078136-6 2005 Western blot confirmed the expression of the recombinant hASBT; functionality was characterized using taurocholic acid. Taurocholic Acid 102-118 solute carrier family 10 member 2 Homo sapiens 57-62 16078136-7 2005 RESULTS: In the selected clone, hASBT-mediated taurocholate permeability across hASBT-MDCK monolayers was almost 25-fold higher with sodium, than without sodium where hASBT is not functional. Taurocholic Acid 47-59 solute carrier family 10 member 2 Homo sapiens 32-37 16078136-7 2005 RESULTS: In the selected clone, hASBT-mediated taurocholate permeability across hASBT-MDCK monolayers was almost 25-fold higher with sodium, than without sodium where hASBT is not functional. Taurocholic Acid 47-59 solute carrier family 10 member 2 Homo sapiens 80-85 16078136-7 2005 RESULTS: In the selected clone, hASBT-mediated taurocholate permeability across hASBT-MDCK monolayers was almost 25-fold higher with sodium, than without sodium where hASBT is not functional. Taurocholic Acid 47-59 solute carrier family 10 member 2 Homo sapiens 80-85 16078136-7 2005 RESULTS: In the selected clone, hASBT-mediated taurocholate permeability across hASBT-MDCK monolayers was almost 25-fold higher with sodium, than without sodium where hASBT is not functional. Sodium 133-139 solute carrier family 10 member 2 Homo sapiens 32-37 16078136-7 2005 RESULTS: In the selected clone, hASBT-mediated taurocholate permeability across hASBT-MDCK monolayers was almost 25-fold higher with sodium, than without sodium where hASBT is not functional. Sodium 133-139 solute carrier family 10 member 2 Homo sapiens 80-85 16078136-7 2005 RESULTS: In the selected clone, hASBT-mediated taurocholate permeability across hASBT-MDCK monolayers was almost 25-fold higher with sodium, than without sodium where hASBT is not functional. Sodium 133-139 solute carrier family 10 member 2 Homo sapiens 80-85 16078136-7 2005 RESULTS: In the selected clone, hASBT-mediated taurocholate permeability across hASBT-MDCK monolayers was almost 25-fold higher with sodium, than without sodium where hASBT is not functional. Sodium 154-160 solute carrier family 10 member 2 Homo sapiens 32-37 16078136-8 2005 In the presence of sodium, taurocholate and mannitol permeabilities were 23.0x10(-6) cm/sec and 2.60x10(-6) cm/s, respectively, indicating high hASBT functionality and monolayer integrity. Sodium 19-25 solute carrier family 10 member 2 Homo sapiens 144-149 16078136-8 2005 In the presence of sodium, taurocholate and mannitol permeabilities were 23.0x10(-6) cm/sec and 2.60x10(-6) cm/s, respectively, indicating high hASBT functionality and monolayer integrity. Taurocholic Acid 27-39 solute carrier family 10 member 2 Homo sapiens 144-149 16078136-8 2005 In the presence of sodium, taurocholate and mannitol permeabilities were 23.0x10(-6) cm/sec and 2.60x10(-6) cm/s, respectively, indicating high hASBT functionality and monolayer integrity. Mannitol 44-52 solute carrier family 10 member 2 Homo sapiens 144-149 16078136-10 2005 Taurocholate uptake and inhibition kinetic parameters from hASBT-MDCK were similar to those obtained from hASBT-COS7 model, confirming hASBT functionality in hASBT-MDCK. Taurocholic Acid 0-12 solute carrier family 10 member 2 Homo sapiens 59-64 15304498-2 2004 Apical sodium-dependent bile acid transporter (ASBT) (SLC10A2), only expressed in the liver on the cholangiocyte apical membrane, is rapidly regulated in response to inflammation and bile acids. Bile Acids and Salts 183-193 solute carrier family 10 member 2 Homo sapiens 54-61 15952798-0 2005 Site-directed mutagenesis and use of bile acid-MTS conjugates to probe the role of cysteines in the human apical sodium-dependent bile acid transporter (SLC10A2). Bile Acids and Salts 37-46 solute carrier family 10 member 2 Homo sapiens 153-160 15952798-0 2005 Site-directed mutagenesis and use of bile acid-MTS conjugates to probe the role of cysteines in the human apical sodium-dependent bile acid transporter (SLC10A2). Cysteine 83-92 solute carrier family 10 member 2 Homo sapiens 153-160 15952798-2 2005 Biochemical modification of conserved cysteine residues has suggested their direct involvement in hASBT function. Cysteine 38-46 solute carrier family 10 member 2 Homo sapiens 98-103 15952798-3 2005 In the present study, we developed novel methanethiosulfonyl (MTS)-bile salt derivatives and describe their reactivity toward hASBT and its mutants. methanethiosulfonyl 41-60 solute carrier family 10 member 2 Homo sapiens 126-131 15952798-3 2005 In the present study, we developed novel methanethiosulfonyl (MTS)-bile salt derivatives and describe their reactivity toward hASBT and its mutants. mts) 62-66 solute carrier family 10 member 2 Homo sapiens 126-131 15952798-3 2005 In the present study, we developed novel methanethiosulfonyl (MTS)-bile salt derivatives and describe their reactivity toward hASBT and its mutants. Bile Acids and Salts 67-76 solute carrier family 10 member 2 Homo sapiens 126-131 15952798-12 2005 Overall, bile acid-MTS conjugates can serve as novel and powerful tools to probe the role of endogenous as well as engineered Cys residues and, ultimately, aid in defining their role in the bile acid binding region(s) of hASBT. Bile Acids and Salts 9-18 solute carrier family 10 member 2 Homo sapiens 221-226 15952798-12 2005 Overall, bile acid-MTS conjugates can serve as novel and powerful tools to probe the role of endogenous as well as engineered Cys residues and, ultimately, aid in defining their role in the bile acid binding region(s) of hASBT. Bile Acids and Salts 190-199 solute carrier family 10 member 2 Homo sapiens 221-226 15604201-1 2005 Bile acids are efficiently absorbed from the intestinal lumen via the ileal apical sodium-dependent bile acid transporter (ASBT). Bile Acids and Salts 0-10 solute carrier family 10 member 2 Homo sapiens 123-127 15604201-2 2005 ASBT function is essential for maintenance of cholesterol homeostasis in the body. Cholesterol 46-57 solute carrier family 10 member 2 Homo sapiens 0-4 15604201-3 2005 The molecular mechanisms of the direct effect of cholesterol on human ASBT function and expression are not entirely understood. Cholesterol 49-60 solute carrier family 10 member 2 Homo sapiens 70-74 15604201-4 2005 The present studies were undertaken to establish a suitable in vitro experimental model to study human ASBT function and its regulation by cholesterol. Cholesterol 139-150 solute carrier family 10 member 2 Homo sapiens 103-107 15604201-13 2005 These data provide novel evidence for the direct regulation of human ASBT function by cholesterol and suggest that this phenomenon may play a central role in cholesterol homeostasis. Cholesterol 86-97 solute carrier family 10 member 2 Homo sapiens 69-73 15604201-13 2005 These data provide novel evidence for the direct regulation of human ASBT function by cholesterol and suggest that this phenomenon may play a central role in cholesterol homeostasis. Cholesterol 158-169 solute carrier family 10 member 2 Homo sapiens 69-73 15304498-2 2004 Apical sodium-dependent bile acid transporter (ASBT) (SLC10A2), only expressed in the liver on the cholangiocyte apical membrane, is rapidly regulated in response to inflammation and bile acids. Bile Acids and Salts 183-193 solute carrier family 10 member 2 Homo sapiens 0-45 15304498-2 2004 Apical sodium-dependent bile acid transporter (ASBT) (SLC10A2), only expressed in the liver on the cholangiocyte apical membrane, is rapidly regulated in response to inflammation and bile acids. Bile Acids and Salts 183-193 solute carrier family 10 member 2 Homo sapiens 47-51 15304498-5 2004 Treatment with MG-132, a proteasome inhibitor, causes time-dependent increased ASBT levels and increased intracellular accumulation of ASBT. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 15-21 solute carrier family 10 member 2 Homo sapiens 79-83 15304498-5 2004 Treatment with MG-132, a proteasome inhibitor, causes time-dependent increased ASBT levels and increased intracellular accumulation of ASBT. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 15-21 solute carrier family 10 member 2 Homo sapiens 135-139 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Serine 179-185 solute carrier family 10 member 2 Homo sapiens 108-112 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Serine 179-185 solute carrier family 10 member 2 Homo sapiens 108-112 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Threonine 186-195 solute carrier family 10 member 2 Homo sapiens 108-112 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Threonine 186-195 solute carrier family 10 member 2 Homo sapiens 108-112 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Serine 236-239 solute carrier family 10 member 2 Homo sapiens 28-32 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Serine 236-239 solute carrier family 10 member 2 Homo sapiens 108-112 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Serine 236-239 solute carrier family 10 member 2 Homo sapiens 108-112 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Threonine 248-251 solute carrier family 10 member 2 Homo sapiens 28-32 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Threonine 248-251 solute carrier family 10 member 2 Homo sapiens 108-112 15304498-9 2004 These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. Threonine 248-251 solute carrier family 10 member 2 Homo sapiens 108-112 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Bile Acids and Salts 111-121 solute carrier family 10 member 2 Homo sapiens 4-49 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Cholesterol 146-157 solute carrier family 10 member 2 Homo sapiens 51-55 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Bile Acids and Salts 111-121 solute carrier family 10 member 2 Homo sapiens 51-55 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Bile Acids and Salts 111-121 solute carrier family 10 member 2 Homo sapiens 57-64 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Cholesterol 146-157 solute carrier family 10 member 2 Homo sapiens 4-49 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Cholesterol 146-157 solute carrier family 10 member 2 Homo sapiens 57-64 14980661-0 2004 A novel class of apical sodium-dependent bile acid transporter inhibitors: the amphiphilic 4-oxo-1-phenyl-1,4-dihydroquinoline derivatives. 4-oxo-1-phenyl-1,4-dihydroquinoline 91-126 solute carrier family 10 member 2 Homo sapiens 17-62 15239098-2 2004 The bile acid responsiveness of human ASBT is unknown. Bile Acids and Salts 4-13 solute carrier family 10 member 2 Homo sapiens 38-42 15239098-3 2004 The human ASBT promoter linked to a luciferase reporter was studied in Caco-2 cells treated with chenodeoxycholic acid (CDCA) and transfected with expression plasmids for farnesoid X-receptor (FXR), short heterodimer partner (SHP), and retinoic acid receptor/retinoid X receptor (RAR/RXR). Chenodeoxycholic Acid 97-118 solute carrier family 10 member 2 Homo sapiens 10-14 15239098-3 2004 The human ASBT promoter linked to a luciferase reporter was studied in Caco-2 cells treated with chenodeoxycholic acid (CDCA) and transfected with expression plasmids for farnesoid X-receptor (FXR), short heterodimer partner (SHP), and retinoic acid receptor/retinoid X receptor (RAR/RXR). Chenodeoxycholic Acid 120-124 solute carrier family 10 member 2 Homo sapiens 10-14 15239098-4 2004 CDCA treatment of Caco-2 cells led to a 75% reduction in steady-state ASBT messenger RNA levels and a 78% reduction in human ASBT promoter activity. Chenodeoxycholic Acid 0-4 solute carrier family 10 member 2 Homo sapiens 70-74 15239098-4 2004 CDCA treatment of Caco-2 cells led to a 75% reduction in steady-state ASBT messenger RNA levels and a 78% reduction in human ASBT promoter activity. Chenodeoxycholic Acid 0-4 solute carrier family 10 member 2 Homo sapiens 125-129 15239098-6 2004 Site-directed mutagenesis of an RAR/RXR cis element in the human ASBT promoter reduced its activity by 50% and eliminated the bile acid response. Bile Acids and Salts 126-135 solute carrier family 10 member 2 Homo sapiens 65-69 15239098-7 2004 Retinoic acid activated the human ASBT promoter fourfold. Tretinoin 0-13 solute carrier family 10 member 2 Homo sapiens 34-38 15239098-9 2004 Antisense mediated knock-down of SHP in Caco-2 cells partially offset the bile acid mediated repression of ASBT promoter activity. Bile Acids and Salts 74-83 solute carrier family 10 member 2 Homo sapiens 107-111 15239098-10 2004 In conclusion, the human ASBT is positively regulated by retinoic acid. Tretinoin 57-70 solute carrier family 10 member 2 Homo sapiens 25-29 15239098-11 2004 Bile acids induce a negative feedback regulation of human ASBT via an FXR-mediated, SHP-dependent effect upon RAR/RXR activation of ASBT. Bile Acids and Salts 0-10 solute carrier family 10 member 2 Homo sapiens 58-62 15239098-11 2004 Bile acids induce a negative feedback regulation of human ASBT via an FXR-mediated, SHP-dependent effect upon RAR/RXR activation of ASBT. Bile Acids and Salts 0-10 solute carrier family 10 member 2 Homo sapiens 132-136 14980661-1 2004 A series of 4-oxo-1-phenyl-1,4-dihydroquinolines possessing a linker and an ammonio moiety were synthesized and found to inhibit the apical sodium-dependent bile acid transporter (ASBT). 4-oxo-1-phenyl-1,4-dihydroquinolines 12-48 solute carrier family 10 member 2 Homo sapiens 133-178 14980661-1 2004 A series of 4-oxo-1-phenyl-1,4-dihydroquinolines possessing a linker and an ammonio moiety were synthesized and found to inhibit the apical sodium-dependent bile acid transporter (ASBT). 4-oxo-1-phenyl-1,4-dihydroquinolines 12-48 solute carrier family 10 member 2 Homo sapiens 180-184 15832499-1 2004 The objective of this work was to design an acyclovir prodrug that would utilize the human apical sodium-dependent bile acid transporter (hASBT) and enhance acyclovir oral bioavailability. Acyclovir 44-53 solute carrier family 10 member 2 Homo sapiens 138-143 12851823-3 2004 The Na(+)/taurocholate cotransporting polypeptide (NTCP; SLC10A1) and the apical sodium-dependent bile salt transporter (ASBT; SLC10A2) are critical components of the enterohepatic circulation of bile salts. Bile Acids and Salts 196-206 solute carrier family 10 member 2 Homo sapiens 74-119 12851823-3 2004 The Na(+)/taurocholate cotransporting polypeptide (NTCP; SLC10A1) and the apical sodium-dependent bile salt transporter (ASBT; SLC10A2) are critical components of the enterohepatic circulation of bile salts. Bile Acids and Salts 196-206 solute carrier family 10 member 2 Homo sapiens 121-125 12851823-3 2004 The Na(+)/taurocholate cotransporting polypeptide (NTCP; SLC10A1) and the apical sodium-dependent bile salt transporter (ASBT; SLC10A2) are critical components of the enterohepatic circulation of bile salts. Bile Acids and Salts 196-206 solute carrier family 10 member 2 Homo sapiens 127-134 12851823-4 2004 NTCP and ASBT are cotransporters that mediate sodium-dependent, electrogenic uptake of mainly bile salts into hepatocytes (NTCP), biliary epithelial cells, ileal enterocytes and renal proximal tubular cells (ASBT). Sodium 46-52 solute carrier family 10 member 2 Homo sapiens 9-13 12851823-4 2004 NTCP and ASBT are cotransporters that mediate sodium-dependent, electrogenic uptake of mainly bile salts into hepatocytes (NTCP), biliary epithelial cells, ileal enterocytes and renal proximal tubular cells (ASBT). Sodium 46-52 solute carrier family 10 member 2 Homo sapiens 208-212 12851823-4 2004 NTCP and ASBT are cotransporters that mediate sodium-dependent, electrogenic uptake of mainly bile salts into hepatocytes (NTCP), biliary epithelial cells, ileal enterocytes and renal proximal tubular cells (ASBT). Bile Acids and Salts 94-104 solute carrier family 10 member 2 Homo sapiens 9-13 12851823-4 2004 NTCP and ASBT are cotransporters that mediate sodium-dependent, electrogenic uptake of mainly bile salts into hepatocytes (NTCP), biliary epithelial cells, ileal enterocytes and renal proximal tubular cells (ASBT). Bile Acids and Salts 94-104 solute carrier family 10 member 2 Homo sapiens 208-212 15832499-1 2004 The objective of this work was to design an acyclovir prodrug that would utilize the human apical sodium-dependent bile acid transporter (hASBT) and enhance acyclovir oral bioavailability. Acyclovir 157-166 solute carrier family 10 member 2 Homo sapiens 138-143 15832499-3 2004 The affinity of the prodrug for hASBT was determined through inhibition of taurocholate uptake by COS-7 cells transfected with hASBT (hASBT-COS). Taurocholic Acid 75-87 solute carrier family 10 member 2 Homo sapiens 32-37 15832499-3 2004 The affinity of the prodrug for hASBT was determined through inhibition of taurocholate uptake by COS-7 cells transfected with hASBT (hASBT-COS). carbonyl sulfide 98-101 solute carrier family 10 member 2 Homo sapiens 32-37 15832499-5 2004 The prodrug acyclovir valylchenodeoxycholate yielded the highest affinity for hASBT (Ki = 35 microM), showing that chenodeoxycholate is the free bile acid with the greatest affinity for hASBT. acyclovir valylchenodeoxycholate 12-44 solute carrier family 10 member 2 Homo sapiens 78-83 15832499-5 2004 The prodrug acyclovir valylchenodeoxycholate yielded the highest affinity for hASBT (Ki = 35 microM), showing that chenodeoxycholate is the free bile acid with the greatest affinity for hASBT. acyclovir valylchenodeoxycholate 12-44 solute carrier family 10 member 2 Homo sapiens 186-191 15832499-5 2004 The prodrug acyclovir valylchenodeoxycholate yielded the highest affinity for hASBT (Ki = 35 microM), showing that chenodeoxycholate is the free bile acid with the greatest affinity for hASBT. Chenodeoxycholic Acid 27-44 solute carrier family 10 member 2 Homo sapiens 78-83 15832499-5 2004 The prodrug acyclovir valylchenodeoxycholate yielded the highest affinity for hASBT (Ki = 35 microM), showing that chenodeoxycholate is the free bile acid with the greatest affinity for hASBT. Chenodeoxycholic Acid 27-44 solute carrier family 10 member 2 Homo sapiens 186-191 15832499-5 2004 The prodrug acyclovir valylchenodeoxycholate yielded the highest affinity for hASBT (Ki = 35 microM), showing that chenodeoxycholate is the free bile acid with the greatest affinity for hASBT. Bile Acids and Salts 145-154 solute carrier family 10 member 2 Homo sapiens 78-83 15832499-5 2004 The prodrug acyclovir valylchenodeoxycholate yielded the highest affinity for hASBT (Ki = 35 microM), showing that chenodeoxycholate is the free bile acid with the greatest affinity for hASBT. Bile Acids and Salts 145-154 solute carrier family 10 member 2 Homo sapiens 186-191 15832499-8 2004 Relative to cellular uptake studies of acyclovir alone, the cellular uptake from the prodrug resulted in a 16-fold greater acyclovir accumulation within hASBT-COS cells, indicating enhanced permeation properties of the prodrug. Acyclovir 123-132 solute carrier family 10 member 2 Homo sapiens 153-158 15832499-10 2004 The extent of acyclovir uptake in the presence of sodium was 1.4-fold greater than the extent of passive prodrug uptake in the absence of sodium (p = 0.02), indicating translocation of the prodrug by hASBT. Acyclovir 14-23 solute carrier family 10 member 2 Homo sapiens 200-205 12177176-2 2002 Evaluated in vitro, 264W94 dose-dependently inhibited sodium-dependent uptake of 10 micro M [(3)H]taurocholic acid (TC) by rat and monkey brush border membrane vesicles with IC(50)s of 0.24 micro M and 0.41 micro M, and had a competitive profile with K(i) of 0.2 micro M against TC in Chinese hamster ovary cells expressing human IBAT. Sodium 54-60 solute carrier family 10 member 2 Homo sapiens 330-334 14552767-0 2003 A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 1,2-benzothiazepines. 1,2-benzothiazepines 82-102 solute carrier family 10 member 2 Homo sapiens 17-65 14552767-1 2003 A series of 5-aryl-3,3-dibutyl-7-(dimethylamino)-1,2-benzothiazepin-4-ol 1,1-dioxides were prepared and were found to inhibit the apical sodium co-dependent bile acid transporter (ASBT) for the potential treatment for hyperlipidemia. 5-aryl-3,3-dibutyl-7-(dimethylamino)-1,2-benzothiazepin-4-ol 12-72 solute carrier family 10 member 2 Homo sapiens 130-178 14552767-1 2003 A series of 5-aryl-3,3-dibutyl-7-(dimethylamino)-1,2-benzothiazepin-4-ol 1,1-dioxides were prepared and were found to inhibit the apical sodium co-dependent bile acid transporter (ASBT) for the potential treatment for hyperlipidemia. 5-aryl-3,3-dibutyl-7-(dimethylamino)-1,2-benzothiazepin-4-ol 12-72 solute carrier family 10 member 2 Homo sapiens 180-184 12810816-2 2003 SC-435 was identified as a potent inhibitor of ASBT (IC50 = 1.5 nM) in cells transfected with the human ASBT gene. 1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane 0-6 solute carrier family 10 member 2 Homo sapiens 47-51 12810816-2 2003 SC-435 was identified as a potent inhibitor of ASBT (IC50 = 1.5 nM) in cells transfected with the human ASBT gene. 1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane 0-6 solute carrier family 10 member 2 Homo sapiens 104-108 12475240-1 2002 Drug intervention that prevents reabsorption of circulating bile acids by the apical (ileal) sodium/bile acid cotransporter (ASBT) may be a promising new therapy for lowering of plasma cholesterol. Bile Acids and Salts 60-70 solute carrier family 10 member 2 Homo sapiens 125-129 12475240-1 2002 Drug intervention that prevents reabsorption of circulating bile acids by the apical (ileal) sodium/bile acid cotransporter (ASBT) may be a promising new therapy for lowering of plasma cholesterol. Cholesterol 185-196 solute carrier family 10 member 2 Homo sapiens 125-129 12475240-7 2002 The hamster apical SBAT encompassing Ser/Ile in these positions shared the lower sensitivity to 2164U90, as seen with the human ASBT, even though it is identical to the mouse SBAT in the remaining four positions of this region. Serine 37-40 solute carrier family 10 member 2 Homo sapiens 128-132 12475240-10 2002 Inactivation of the human ASBT due to MTS modification of cysteine 270 was shown to be largely abolished when the transporter was preincubated with 2164U90, suggesting that the binding of this benzothiazepine is in the vicinity of position 270. Cysteine 58-66 solute carrier family 10 member 2 Homo sapiens 26-30 12475240-10 2002 Inactivation of the human ASBT due to MTS modification of cysteine 270 was shown to be largely abolished when the transporter was preincubated with 2164U90, suggesting that the binding of this benzothiazepine is in the vicinity of position 270. benzothiazepine 193-208 solute carrier family 10 member 2 Homo sapiens 26-30 14684580-2 2004 Intestinal bile acid absorption is mediated by the apical sodium dependent bile acid transporter ASBT/IBAT (SLC10A2). Bile Acids and Salts 11-20 solute carrier family 10 member 2 Homo sapiens 97-101 14684580-2 2004 Intestinal bile acid absorption is mediated by the apical sodium dependent bile acid transporter ASBT/IBAT (SLC10A2). Bile Acids and Salts 11-20 solute carrier family 10 member 2 Homo sapiens 102-106 14684580-2 2004 Intestinal bile acid absorption is mediated by the apical sodium dependent bile acid transporter ASBT/IBAT (SLC10A2). Bile Acids and Salts 11-20 solute carrier family 10 member 2 Homo sapiens 108-115 14684580-8 2004 In 10 healthy male volunteers, ASBT protein expression was increased 1.34 (0.11)-fold (mean (SEM); p<0.05) after 21 days" intake of budesonide (9 mg/day) whereas expression of the peptide transporter 1 was unaffected. Budesonide 135-145 solute carrier family 10 member 2 Homo sapiens 31-35 14684580-9 2004 Reporter constructs of the human ASBT promoter were activated 15-20-fold by coexpression of the glucocorticoid receptor (GR) and exposure to the GR ligands dexamethasone or budesonide. Dexamethasone 156-169 solute carrier family 10 member 2 Homo sapiens 33-37 14684580-9 2004 Reporter constructs of the human ASBT promoter were activated 15-20-fold by coexpression of the glucocorticoid receptor (GR) and exposure to the GR ligands dexamethasone or budesonide. Budesonide 173-183 solute carrier family 10 member 2 Homo sapiens 33-37 14684580-10 2004 Two glucocorticoid response elements in the ASBT promoter, arranged as inverted hexanucleotide repeats (IR3 elements), conferred inducibility by GR and dexamethasone in a heterologous promoter context and were shown to bind GR in mobility shift assays. hexanucleotide 80-94 solute carrier family 10 member 2 Homo sapiens 44-48 14684580-10 2004 Two glucocorticoid response elements in the ASBT promoter, arranged as inverted hexanucleotide repeats (IR3 elements), conferred inducibility by GR and dexamethasone in a heterologous promoter context and were shown to bind GR in mobility shift assays. Dexamethasone 152-165 solute carrier family 10 member 2 Homo sapiens 44-48 12819193-2 2003 In patients with primary bile acid malabsorption, mutations in the ileal bile acid transporter gene (Slc10a2) lead to congenital diarrhea, steatorrhea, and reduced plasma cholesterol levels. Bile Acids and Salts 25-34 solute carrier family 10 member 2 Homo sapiens 101-108 12819193-2 2003 In patients with primary bile acid malabsorption, mutations in the ileal bile acid transporter gene (Slc10a2) lead to congenital diarrhea, steatorrhea, and reduced plasma cholesterol levels. Cholesterol 171-182 solute carrier family 10 member 2 Homo sapiens 101-108 12562847-1 2003 Discovery of the ileal apical sodium-dependent bile acid transporter (ASBT) permitted development of specific inhibitors of bile acid reabsorption, potentially a new class of cholesterol-lowering agents. Bile Acids and Salts 47-56 solute carrier family 10 member 2 Homo sapiens 70-74 12562847-1 2003 Discovery of the ileal apical sodium-dependent bile acid transporter (ASBT) permitted development of specific inhibitors of bile acid reabsorption, potentially a new class of cholesterol-lowering agents. Cholesterol 175-186 solute carrier family 10 member 2 Homo sapiens 23-68 12562847-1 2003 Discovery of the ileal apical sodium-dependent bile acid transporter (ASBT) permitted development of specific inhibitors of bile acid reabsorption, potentially a new class of cholesterol-lowering agents. Cholesterol 175-186 solute carrier family 10 member 2 Homo sapiens 70-74 12562847-2 2003 In the present study, we tested the hypothesis that combining the novel ASBT inhibitor, SC-435, with the HMG-CoA reductase inhibitor, atorvastatin, would potentiate reductions in LDL cholesterol (LDL-C) and LDL apolipoprotein B (apoB). 1-(4-(4-(3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)butyl)-4-aza-1-azoniabicyclo(2.2.2)octane 88-94 solute carrier family 10 member 2 Homo sapiens 72-76 12663868-2 2003 The bile salt pool undergoes an enterohepatic circulation that is regulated by distinct bile salt transport proteins, including the canalicular bile salt export pump BSEP (ABCB11), the ileal Na(+)-dependent bile salt transporter ISBT (SLC10A2), and the hepatic sinusoidal Na(+)- taurocholate cotransporting polypeptide NTCP (SLC10A1). Bile Acids and Salts 4-13 solute carrier family 10 member 2 Homo sapiens 229-233 12663868-2 2003 The bile salt pool undergoes an enterohepatic circulation that is regulated by distinct bile salt transport proteins, including the canalicular bile salt export pump BSEP (ABCB11), the ileal Na(+)-dependent bile salt transporter ISBT (SLC10A2), and the hepatic sinusoidal Na(+)- taurocholate cotransporting polypeptide NTCP (SLC10A1). Bile Acids and Salts 4-13 solute carrier family 10 member 2 Homo sapiens 235-242 12663868-2 2003 The bile salt pool undergoes an enterohepatic circulation that is regulated by distinct bile salt transport proteins, including the canalicular bile salt export pump BSEP (ABCB11), the ileal Na(+)-dependent bile salt transporter ISBT (SLC10A2), and the hepatic sinusoidal Na(+)- taurocholate cotransporting polypeptide NTCP (SLC10A1). Bile Acids and Salts 88-97 solute carrier family 10 member 2 Homo sapiens 229-233 12663868-2 2003 The bile salt pool undergoes an enterohepatic circulation that is regulated by distinct bile salt transport proteins, including the canalicular bile salt export pump BSEP (ABCB11), the ileal Na(+)-dependent bile salt transporter ISBT (SLC10A2), and the hepatic sinusoidal Na(+)- taurocholate cotransporting polypeptide NTCP (SLC10A1). Bile Acids and Salts 88-97 solute carrier family 10 member 2 Homo sapiens 235-242 12663868-2 2003 The bile salt pool undergoes an enterohepatic circulation that is regulated by distinct bile salt transport proteins, including the canalicular bile salt export pump BSEP (ABCB11), the ileal Na(+)-dependent bile salt transporter ISBT (SLC10A2), and the hepatic sinusoidal Na(+)- taurocholate cotransporting polypeptide NTCP (SLC10A1). Bile Acids and Salts 88-97 solute carrier family 10 member 2 Homo sapiens 229-233 12663868-2 2003 The bile salt pool undergoes an enterohepatic circulation that is regulated by distinct bile salt transport proteins, including the canalicular bile salt export pump BSEP (ABCB11), the ileal Na(+)-dependent bile salt transporter ISBT (SLC10A2), and the hepatic sinusoidal Na(+)- taurocholate cotransporting polypeptide NTCP (SLC10A1). Bile Acids and Salts 88-97 solute carrier family 10 member 2 Homo sapiens 235-242 12475897-5 2003 We here describe the effect of PR835, a drug belonging to a new class of lipid-lowering agents that inhibit the Slc10a2 protein, the intestinal transporter responsible for active uptake of BA. Bile Acids and Salts 189-191 solute carrier family 10 member 2 Homo sapiens 112-119 12055195-1 2002 The apical sodium-dependent bile salt transporter (ASBT/SLC10A2), also called the ileal bile acid transporter, mediates the intestinal absorption of bile salts. Bile Acids and Salts 149-159 solute carrier family 10 member 2 Homo sapiens 51-55 12055195-1 2002 The apical sodium-dependent bile salt transporter (ASBT/SLC10A2), also called the ileal bile acid transporter, mediates the intestinal absorption of bile salts. Bile Acids and Salts 149-159 solute carrier family 10 member 2 Homo sapiens 56-63 12055195-3 2002 Our aim was to characterize the human ASBT gene promoter with respect to regulatory mechanisms that coordinately affect ASBT expression and hepatic lipid and bile salt metabolism. Bile Acids and Salts 158-167 solute carrier family 10 member 2 Homo sapiens 38-42 12177176-2 2002 Evaluated in vitro, 264W94 dose-dependently inhibited sodium-dependent uptake of 10 micro M [(3)H]taurocholic acid (TC) by rat and monkey brush border membrane vesicles with IC(50)s of 0.24 micro M and 0.41 micro M, and had a competitive profile with K(i) of 0.2 micro M against TC in Chinese hamster ovary cells expressing human IBAT. [(3)h]taurocholic acid 92-114 solute carrier family 10 member 2 Homo sapiens 330-334 12177176-2 2002 Evaluated in vitro, 264W94 dose-dependently inhibited sodium-dependent uptake of 10 micro M [(3)H]taurocholic acid (TC) by rat and monkey brush border membrane vesicles with IC(50)s of 0.24 micro M and 0.41 micro M, and had a competitive profile with K(i) of 0.2 micro M against TC in Chinese hamster ovary cells expressing human IBAT. Technetium 116-118 solute carrier family 10 member 2 Homo sapiens 330-334 12177176-8 2002 In conclusion, 264W94 is a potent new cholesterol lowering agent that acts through inhibition of IBAT and exhibits activity in a human model. Cholesterol 38-49 solute carrier family 10 member 2 Homo sapiens 97-101 10860504-3 2000 The sodium-activated uptake of 30 microM [(14)C]glycocholate (GC) via the ileal (IBAT) and liver (LBAT) transporters was 30-40 times higher than GC uptake in a sodium-free background. Sodium 4-10 solute carrier family 10 member 2 Homo sapiens 81-85 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. Bile Acids and Salts 48-58 solute carrier family 10 member 2 Homo sapiens 130-175 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. Bile Acids and Salts 48-58 solute carrier family 10 member 2 Homo sapiens 181-185 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. Bile Acids and Salts 48-58 solute carrier family 10 member 2 Homo sapiens 284-288 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. Bile Acids and Salts 73-83 solute carrier family 10 member 2 Homo sapiens 130-175 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. Bile Acids and Salts 73-83 solute carrier family 10 member 2 Homo sapiens 181-185 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. Bile Acids and Salts 73-83 solute carrier family 10 member 2 Homo sapiens 284-288 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. tasbt 290-295 solute carrier family 10 member 2 Homo sapiens 130-175 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. tasbt 290-295 solute carrier family 10 member 2 Homo sapiens 176-180 11826283-6 2002 In bile ductules, a minor portion of protonated bile acids and monomeric bile salts are reabsorbed by non-ionic diffusion and the apical sodium-dependent bile salt transporter Asbt/ASBT, transported back into the periductular capillary plexus by Mrp3/MRP3 [and/or a truncated form of Asbt (tAsbt)], and subjected to cholehepatic shunting. tasbt 290-295 solute carrier family 10 member 2 Homo sapiens 181-185 11826283-7 2002 The major portion of biliary bile salts is aggregated into mixed micelles and transported into the intestine, where they are reabsorbed by apical Oatp3, the apical sodium-dependent bile salt transporter (ASBT), cytosolic intestinal bile acid-binding protein (IBABP), and basolateral Mrp3/MRP3 and tAsbt. Bile Acids and Salts 29-39 solute carrier family 10 member 2 Homo sapiens 157-202 11826283-7 2002 The major portion of biliary bile salts is aggregated into mixed micelles and transported into the intestine, where they are reabsorbed by apical Oatp3, the apical sodium-dependent bile salt transporter (ASBT), cytosolic intestinal bile acid-binding protein (IBABP), and basolateral Mrp3/MRP3 and tAsbt. Bile Acids and Salts 29-39 solute carrier family 10 member 2 Homo sapiens 204-208 11826283-7 2002 The major portion of biliary bile salts is aggregated into mixed micelles and transported into the intestine, where they are reabsorbed by apical Oatp3, the apical sodium-dependent bile salt transporter (ASBT), cytosolic intestinal bile acid-binding protein (IBABP), and basolateral Mrp3/MRP3 and tAsbt. oatp3 146-151 solute carrier family 10 member 2 Homo sapiens 204-208 11808323-1 2002 The ileal Na+/bile acid cotransporter (IBAT) maintains the reabsorption of bile acids from the ileum in the enterohepatic circulation of bile acids. Bile Acids and Salts 75-85 solute carrier family 10 member 2 Homo sapiens 4-37 11808323-1 2002 The ileal Na+/bile acid cotransporter (IBAT) maintains the reabsorption of bile acids from the ileum in the enterohepatic circulation of bile acids. Bile Acids and Salts 75-85 solute carrier family 10 member 2 Homo sapiens 39-43 11808323-1 2002 The ileal Na+/bile acid cotransporter (IBAT) maintains the reabsorption of bile acids from the ileum in the enterohepatic circulation of bile acids. Bile Acids and Salts 137-147 solute carrier family 10 member 2 Homo sapiens 4-37 11808323-1 2002 The ileal Na+/bile acid cotransporter (IBAT) maintains the reabsorption of bile acids from the ileum in the enterohepatic circulation of bile acids. Bile Acids and Salts 137-147 solute carrier family 10 member 2 Homo sapiens 39-43 11808323-3 2002 Inhibition of IBAT by specific IBAT inhibitors such as S-8921 has been proven to lower serum cholesterol in a variety of experimental animals. Cholesterol 93-104 solute carrier family 10 member 2 Homo sapiens 14-18 11808323-3 2002 Inhibition of IBAT by specific IBAT inhibitors such as S-8921 has been proven to lower serum cholesterol in a variety of experimental animals. Cholesterol 93-104 solute carrier family 10 member 2 Homo sapiens 31-35 11742882-6 2001 In transfected COS cells, the V98I, V159I, and A171S isoforms all transported bile acids similar to the wild-type SLC10A2. Bile Acids and Salts 78-88 solute carrier family 10 member 2 Homo sapiens 114-121 11589382-1 2001 BACKGROUND: A congenital form of idiopathic intestinal bile acid malabsorption (IBAM) has been associated with dysfunctional mutations in the ileal apical sodium-dependent bile acid transporter (ASBT). ibam 80-84 solute carrier family 10 member 2 Homo sapiens 195-199 11535543-2 2001 The ileal sodium-dependent bile acid transporter (ISBT) is a crucial player in the enterohepatic circulation of bile acids. Bile Acids and Salts 112-122 solute carrier family 10 member 2 Homo sapiens 4-48 11535543-2 2001 The ileal sodium-dependent bile acid transporter (ISBT) is a crucial player in the enterohepatic circulation of bile acids. Bile Acids and Salts 112-122 solute carrier family 10 member 2 Homo sapiens 50-54 11535543-3 2001 Genetic defects in ISBT may result in malabsorption of bile acids and a loss of bile acids into the large intestine, with a resultant increase in the cytotoxic secondary bile acids in the colon. Bile Acids and Salts 55-65 solute carrier family 10 member 2 Homo sapiens 19-23 11535543-3 2001 Genetic defects in ISBT may result in malabsorption of bile acids and a loss of bile acids into the large intestine, with a resultant increase in the cytotoxic secondary bile acids in the colon. Bile Acids and Salts 80-90 solute carrier family 10 member 2 Homo sapiens 19-23 11535543-3 2001 Genetic defects in ISBT may result in malabsorption of bile acids and a loss of bile acids into the large intestine, with a resultant increase in the cytotoxic secondary bile acids in the colon. Bile Acids and Salts 80-90 solute carrier family 10 member 2 Homo sapiens 19-23 11535543-8 2001 This initial observation of an association between a polymorphism in the SLC10A2 gene and the risk of colorectal adenomatous polyps would, if confirmed by other studies, support the role of bile acids in the carcinogenesis of colorectal cancer. Bile Acids and Salts 190-200 solute carrier family 10 member 2 Homo sapiens 73-80 11396803-4 2001 Exon skipping leads to a truncated version of ASBT, which sorts to the basolateral surface and mediates efflux of bile salts. Bile Acids and Salts 114-124 solute carrier family 10 member 2 Homo sapiens 46-50 11396803-5 2001 Inherited mutation of ASBT leads to congenital diarrhea secondary to bile acid malabsorption. Bile Acids and Salts 69-78 solute carrier family 10 member 2 Homo sapiens 22-26 11396803-8 2001 The bile acid responsiveness of the ASBT gene is not clear and may be dependent on both the experimental model used and the species being investigated. Bile Acids and Salts 4-13 solute carrier family 10 member 2 Homo sapiens 36-40 11230727-3 2001 Expression of the apical sodium-dependent bile acid transporter (ASBT) and of the organic anion transporting polypeptide (OATP-A) was detected and associated with sodium-dependent and sodium-independent [(3)H]taurocholate uptake in BEC. Sodium 25-31 solute carrier family 10 member 2 Homo sapiens 65-69 11230727-3 2001 Expression of the apical sodium-dependent bile acid transporter (ASBT) and of the organic anion transporting polypeptide (OATP-A) was detected and associated with sodium-dependent and sodium-independent [(3)H]taurocholate uptake in BEC. Sodium 163-169 solute carrier family 10 member 2 Homo sapiens 18-63 11230727-3 2001 Expression of the apical sodium-dependent bile acid transporter (ASBT) and of the organic anion transporting polypeptide (OATP-A) was detected and associated with sodium-dependent and sodium-independent [(3)H]taurocholate uptake in BEC. Sodium 163-169 solute carrier family 10 member 2 Homo sapiens 65-69 11230727-3 2001 Expression of the apical sodium-dependent bile acid transporter (ASBT) and of the organic anion transporting polypeptide (OATP-A) was detected and associated with sodium-dependent and sodium-independent [(3)H]taurocholate uptake in BEC. Taurocholic Acid 209-221 solute carrier family 10 member 2 Homo sapiens 18-63 11230727-3 2001 Expression of the apical sodium-dependent bile acid transporter (ASBT) and of the organic anion transporting polypeptide (OATP-A) was detected and associated with sodium-dependent and sodium-independent [(3)H]taurocholate uptake in BEC. Taurocholic Acid 209-221 solute carrier family 10 member 2 Homo sapiens 65-69 11230727-9 2001 These results provide evidence that bile acids may be transported mainly via ASBT in human gallbladder BEC and stimulate hydroelectrolytic and mucin secretion in these cells. Bile Acids and Salts 36-46 solute carrier family 10 member 2 Homo sapiens 77-81 10974045-12 2000 We conclude that impaired absorption of bile acid in type IV hypertriglyceridemia results from diminished expression of the ASBT gene in terminal ileum. Bile Acids and Salts 40-49 solute carrier family 10 member 2 Homo sapiens 124-128 10860504-3 2000 The sodium-activated uptake of 30 microM [(14)C]glycocholate (GC) via the ileal (IBAT) and liver (LBAT) transporters was 30-40 times higher than GC uptake in a sodium-free background. [(14)c]glycocholate 41-60 solute carrier family 10 member 2 Homo sapiens 81-85 10860504-3 2000 The sodium-activated uptake of 30 microM [(14)C]glycocholate (GC) via the ileal (IBAT) and liver (LBAT) transporters was 30-40 times higher than GC uptake in a sodium-free background. gallocatechol 62-64 solute carrier family 10 member 2 Homo sapiens 81-85 10860504-6 2000 Uptake of labeled bile acids was inhibited both by the specific IBAT inhibitor, 2164U90, and by various bile acids. Bile Acids and Salts 18-28 solute carrier family 10 member 2 Homo sapiens 64-68 9109432-1 1997 Primary bile acid malabsorption (PBAM) is an idiopathic intestinal disorder associated with congenital diarrhea, steatorrhea, interruption of the enterohepatic circulation of bile acids, and reduced plasma cholesterol levels. Bile Acids and Salts 175-185 solute carrier family 10 member 2 Homo sapiens 33-37 10329102-5 1999 We found that a functional ASBT is expressed by H69 cells as demonstrated by RT-PCR and bile acid uptake studies. Bile Acids and Salts 88-97 solute carrier family 10 member 2 Homo sapiens 27-31 9658552-6 1998 IBat was significantly lower with 2 x QRS as compared with 2 x URS (13.43 +/- 1.0 vs. 14.20 +/- 1.2 microA, p < 0.01) and as compared with 3 x tRS (13.99 +/- 1.2 microA, p < 0.05). Peptichemio 63-66 solute carrier family 10 member 2 Homo sapiens 0-4 9626753-1 1997 The Na(+)-bile acid cotransporters NTCP and ASBT are largely responsible for the Na(+)-dependent bile acid uptake in hepatocytes and intestinal epithelial cells, respectively. Bile Acids and Salts 10-19 solute carrier family 10 member 2 Homo sapiens 44-48 10698453-0 2000 A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 2,3-disubstituted-4-phenylquinolines. 2,3-disubstituted-4-phenylquinolines 82-118 solute carrier family 10 member 2 Homo sapiens 17-65 10698453-1 2000 A series of 2,3-disubstituted-4-phenylquinolines were prepared and were found to inhibit the apical sodium co-dependent bile acid transporter (ASBT). 2,3-disubstituted-4-phenylquinolines 12-48 solute carrier family 10 member 2 Homo sapiens 93-141 10698453-1 2000 A series of 2,3-disubstituted-4-phenylquinolines were prepared and were found to inhibit the apical sodium co-dependent bile acid transporter (ASBT). 2,3-disubstituted-4-phenylquinolines 12-48 solute carrier family 10 member 2 Homo sapiens 143-147 9109432-1 1997 Primary bile acid malabsorption (PBAM) is an idiopathic intestinal disorder associated with congenital diarrhea, steatorrhea, interruption of the enterohepatic circulation of bile acids, and reduced plasma cholesterol levels. Cholesterol 206-217 solute carrier family 10 member 2 Homo sapiens 33-37 9109432-10 1997 These findings establish that SLC10A2 mutations can cause PBAM and underscore the ileal Na+/bile acid cotransporter"s role in intestinal reclamation of bile acids. Bile Acids and Salts 152-162 solute carrier family 10 member 2 Homo sapiens 30-37 34181976-4 2021 The present mini-review provides a brief summary of recent progress of the application of bile acid-drug conjugates based primarily on ASBT, NTCP, and OATP, with the hope of contributing to subsequent research. Bile Acids and Salts 90-99 solute carrier family 10 member 2 Homo sapiens 135-139 34638773-8 2021 Placental SLC10A2 (ASBT), SLCO4A1 (OATP4A1), and ABCC2 mRNA levels were positively correlated with BA concentrations in ICP. Bile Acids and Salts 99-101 solute carrier family 10 member 2 Homo sapiens 10-17 34638773-8 2021 Placental SLC10A2 (ASBT), SLCO4A1 (OATP4A1), and ABCC2 mRNA levels were positively correlated with BA concentrations in ICP. Bile Acids and Salts 99-101 solute carrier family 10 member 2 Homo sapiens 19-23 33782042-7 2021 These novel fluorescent probes were able to block substrate transport in a concentration-dependent manner of NTCP, OATP1B1, OATP1B3, OATP2B1, BSEP and intestinal apical sodium-dependent bile salt transporter (ASBT). Sodium 169-175 solute carrier family 10 member 2 Homo sapiens 209-213 33782042-7 2021 These novel fluorescent probes were able to block substrate transport in a concentration-dependent manner of NTCP, OATP1B1, OATP1B3, OATP2B1, BSEP and intestinal apical sodium-dependent bile salt transporter (ASBT). Bile Acids and Salts 186-195 solute carrier family 10 member 2 Homo sapiens 209-213 33782042-10 2021 Significance Statement Synthetic modification of common bile acids by attachment of small organic fluorescent dyes to the bile acid side chain resulted in bright, fluorescent probes that interact with hepatic and intestinal organic anion (OATP1B1, OATP1B3, OATP2B1), bile salt uptake (NTCP, ASBT) and bile salt efflux (BSEP, MRP2) transporters. Bile Acids and Salts 56-66 solute carrier family 10 member 2 Homo sapiens 291-295 33782042-10 2021 Significance Statement Synthetic modification of common bile acids by attachment of small organic fluorescent dyes to the bile acid side chain resulted in bright, fluorescent probes that interact with hepatic and intestinal organic anion (OATP1B1, OATP1B3, OATP2B1), bile salt uptake (NTCP, ASBT) and bile salt efflux (BSEP, MRP2) transporters. Bile Acids and Salts 56-65 solute carrier family 10 member 2 Homo sapiens 291-295 33782042-10 2021 Significance Statement Synthetic modification of common bile acids by attachment of small organic fluorescent dyes to the bile acid side chain resulted in bright, fluorescent probes that interact with hepatic and intestinal organic anion (OATP1B1, OATP1B3, OATP2B1), bile salt uptake (NTCP, ASBT) and bile salt efflux (BSEP, MRP2) transporters. Bile Acids and Salts 267-276 solute carrier family 10 member 2 Homo sapiens 291-295 33782042-10 2021 Significance Statement Synthetic modification of common bile acids by attachment of small organic fluorescent dyes to the bile acid side chain resulted in bright, fluorescent probes that interact with hepatic and intestinal organic anion (OATP1B1, OATP1B3, OATP2B1), bile salt uptake (NTCP, ASBT) and bile salt efflux (BSEP, MRP2) transporters. Bile Acids and Salts 301-310 solute carrier family 10 member 2 Homo sapiens 291-295 35626847-6 2022 Attempting to reduce the total bile acids, we initiated off-label use of the ileal bile acid transporter (IBAT) inhibitor Elobixibat (Goofice ), later converted to Odevixibat (Bylvay ). elobixibat 122-132 solute carrier family 10 member 2 Homo sapiens 77-104 34346218-0 2021 Modulatory Effect of Theaflavins on Apical Sodium-Dependent Bile Acid Transporter (ASBT) Activity. theaflavin 21-32 solute carrier family 10 member 2 Homo sapiens 36-81 34346218-0 2021 Modulatory Effect of Theaflavins on Apical Sodium-Dependent Bile Acid Transporter (ASBT) Activity. theaflavin 21-32 solute carrier family 10 member 2 Homo sapiens 83-87 34346218-1 2021 Inhibiting apical sodium-dependent bile acid transporter (ASBT) has been identified as a potential strategy to reduce plasma cholesterol levels. Cholesterol 125-136 solute carrier family 10 member 2 Homo sapiens 11-56 34346218-1 2021 Inhibiting apical sodium-dependent bile acid transporter (ASBT) has been identified as a potential strategy to reduce plasma cholesterol levels. Cholesterol 125-136 solute carrier family 10 member 2 Homo sapiens 58-62 34346218-2 2021 Thus, in this study, we aimed to identify polyphenols that inhibited ASBT activity and to elucidate their mechanism. Polyphenols 42-53 solute carrier family 10 member 2 Homo sapiens 69-73 34346218-3 2021 ASBT is responsible for most of the taurocholic acid (TC) uptake in Caco-2 cells. Taurocholic Acid 36-52 solute carrier family 10 member 2 Homo sapiens 0-4 34346218-3 2021 ASBT is responsible for most of the taurocholic acid (TC) uptake in Caco-2 cells. Taurocholic Acid 54-56 solute carrier family 10 member 2 Homo sapiens 0-4 34346218-5 2021 The results from the TC uptake assay using N-acetylcysteine suggested that the inhibitory effect of TF2A and TF2B was attributed to the oxidization of their benzotropolone rings and their covalent bonding with ASBT"s cysteine. Taurocholic Acid 21-23 solute carrier family 10 member 2 Homo sapiens 210-214 34346218-5 2021 The results from the TC uptake assay using N-acetylcysteine suggested that the inhibitory effect of TF2A and TF2B was attributed to the oxidization of their benzotropolone rings and their covalent bonding with ASBT"s cysteine. Acetylcysteine 43-59 solute carrier family 10 member 2 Homo sapiens 210-214 34346218-5 2021 The results from the TC uptake assay using N-acetylcysteine suggested that the inhibitory effect of TF2A and TF2B was attributed to the oxidization of their benzotropolone rings and their covalent bonding with ASBT"s cysteine. benzotropolone 157-171 solute carrier family 10 member 2 Homo sapiens 210-214 34346218-5 2021 The results from the TC uptake assay using N-acetylcysteine suggested that the inhibitory effect of TF2A and TF2B was attributed to the oxidization of their benzotropolone rings and their covalent bonding with ASBT"s cysteine. Cysteine 217-225 solute carrier family 10 member 2 Homo sapiens 210-214 34346218-6 2021 TC uptake was reduced in the COS-7 cells expressing recombinant ASBT whose cysteine residues were mutated to alanine. Taurocholic Acid 0-2 solute carrier family 10 member 2 Homo sapiens 64-68 34346218-6 2021 TC uptake was reduced in the COS-7 cells expressing recombinant ASBT whose cysteine residues were mutated to alanine. Cysteine 75-83 solute carrier family 10 member 2 Homo sapiens 64-68 34346218-6 2021 TC uptake was reduced in the COS-7 cells expressing recombinant ASBT whose cysteine residues were mutated to alanine. Alanine 109-116 solute carrier family 10 member 2 Homo sapiens 64-68 34248551-7 2021 To our knowledge, this is the first report to perform a combined multimodal treatment with HDR-ISBT for pSCC suspected as a secondary cancer due to LDR-BT. ldr-bt 148-154 solute carrier family 10 member 2 Homo sapiens 95-99 34079822-3 2021 Its intestinal counterpart, apical sodium-dependent bile acid transporter ASBT, is responsible for the reabsorption of bile acids from the intestinal lumen. Sodium 35-41 solute carrier family 10 member 2 Homo sapiens 74-78 34079822-3 2021 Its intestinal counterpart, apical sodium-dependent bile acid transporter ASBT, is responsible for the reabsorption of bile acids from the intestinal lumen. Bile Acids and Salts 52-61 solute carrier family 10 member 2 Homo sapiens 74-78 34079822-3 2021 Its intestinal counterpart, apical sodium-dependent bile acid transporter ASBT, is responsible for the reabsorption of bile acids from the intestinal lumen. Bile Acids and Salts 119-129 solute carrier family 10 member 2 Homo sapiens 74-78 34079822-7 2021 Taurolithocholic acid (TLC) was identified as the first common substrate of NTCP, ASBT and SOAT with K m values of 18.4, 5.9, and 19.3 microM, respectively. Taurolithocholic Acid 0-21 solute carrier family 10 member 2 Homo sapiens 82-86 34079822-7 2021 Taurolithocholic acid (TLC) was identified as the first common substrate of NTCP, ASBT and SOAT with K m values of 18.4, 5.9, and 19.3 microM, respectively. Taurolithocholic Acid 23-26 solute carrier family 10 member 2 Homo sapiens 82-86 35224661-7 2022 Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes. deoxynivalenol 12-15 solute carrier family 10 member 2 Homo sapiens 69-114 35224661-7 2022 Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes. deoxynivalenol 12-15 solute carrier family 10 member 2 Homo sapiens 116-120 35224661-7 2022 Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes. GW 4064 298-304 solute carrier family 10 member 2 Homo sapiens 69-114 35224661-7 2022 Exposure to DON downregulates expression of the genes coding for the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP) and the organic solute transporter alpha (OSTalpha), and it counteracts the agonist activity of Farnesoid X receptor (FXR) agonist GW4064 on these genes. GW 4064 298-304 solute carrier family 10 member 2 Homo sapiens 116-120 35507739-0 2022 Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study. Lopixibat 0-11 solute carrier family 10 member 2 Homo sapiens 50-54 35176336-3 2022 In our previous study, we confirmed the efficacy of glycocholic acid-conjugated polystyrene nanoparticles (GCPN) on apical sodium bile acid transporter (ASBT)-expressed SK-BR-3 cells. Glycocholic Acid 52-68 solute carrier family 10 member 2 Homo sapiens 116-151 35176336-3 2022 In our previous study, we confirmed the efficacy of glycocholic acid-conjugated polystyrene nanoparticles (GCPN) on apical sodium bile acid transporter (ASBT)-expressed SK-BR-3 cells. Glycocholic Acid 52-68 solute carrier family 10 member 2 Homo sapiens 153-157 35176336-3 2022 In our previous study, we confirmed the efficacy of glycocholic acid-conjugated polystyrene nanoparticles (GCPN) on apical sodium bile acid transporter (ASBT)-expressed SK-BR-3 cells. Polystyrenes 80-91 solute carrier family 10 member 2 Homo sapiens 116-151 35176336-3 2022 In our previous study, we confirmed the efficacy of glycocholic acid-conjugated polystyrene nanoparticles (GCPN) on apical sodium bile acid transporter (ASBT)-expressed SK-BR-3 cells. Polystyrenes 80-91 solute carrier family 10 member 2 Homo sapiens 153-157 34813049-1 2022 Maralixibat (Livmarli ) is an orally-administered, small-molecule ileal bile acid transporter (IBAT) inhibitor being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia. Lopixibat 0-11 solute carrier family 10 member 2 Homo sapiens 95-99 34813049-1 2022 Maralixibat (Livmarli ) is an orally-administered, small-molecule ileal bile acid transporter (IBAT) inhibitor being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia. Bile Acids and Salts 72-81 solute carrier family 10 member 2 Homo sapiens 95-99 33359100-0 2021 Dissecting the Conformational Dynamics of the Bile Acid Transporter Homologue ASBTNM. Bile Acids and Salts 46-55 solute carrier family 10 member 2 Homo sapiens 78-84 34009974-2 2021 Single-crystal X-ray diffraction suggests that Sr2Nb6O13F8 4H2O, crystallizing in the orthorhombic centrosymmetric space group, Pbam (No. sr2nb6o13f8 4h2o 47-63 solute carrier family 10 member 2 Homo sapiens 128-132 33630750-9 2021 This can be obtained by reducing bile acid absorption using bile acid sequestering agents (approved for the treatment of type 2 diabetes) or inhibitors of intestinal bile acid transporters, i.e., the apical sodium-dependent bile acid transporter (ASBT). Bile Acids and Salts 33-42 solute carrier family 10 member 2 Homo sapiens 200-245 33630750-9 2021 This can be obtained by reducing bile acid absorption using bile acid sequestering agents (approved for the treatment of type 2 diabetes) or inhibitors of intestinal bile acid transporters, i.e., the apical sodium-dependent bile acid transporter (ASBT). Bile Acids and Salts 33-42 solute carrier family 10 member 2 Homo sapiens 247-251 33278408-5 2021 Concentration dependent uptake of tauro-nor-THCA-24-DBD in ASBT-expressing oocytes was saturable with Km 122 muM and Vmax 1.49 pmol/oocyte/30 min for peak 1, 30.7 muM and 1.34 pmol/oocyte/30 min for peak 2, and 40.6 muM and 2.36 pmol/oocyte/30 min for sum, respectively. tauro-nor-thca-24-dbd 34-55 solute carrier family 10 member 2 Homo sapiens 59-63 33278408-8 2021 Additionally, these uptakes were decreased by elobixibat, a selective ASBT inhibitor. elobixibat 46-56 solute carrier family 10 member 2 Homo sapiens 70-74 33278408-9 2021 Accordingly, it was concluded that tauro-nor-THCA-24-DBD is a substrate of ASBT and useful to evaluate the intestinal ASBT transport activity. tauro-nor-thca-24-dbd 35-56 solute carrier family 10 member 2 Homo sapiens 75-79 33278408-9 2021 Accordingly, it was concluded that tauro-nor-THCA-24-DBD is a substrate of ASBT and useful to evaluate the intestinal ASBT transport activity. tauro-nor-thca-24-dbd 35-56 solute carrier family 10 member 2 Homo sapiens 118-122 33921515-3 2021 The present study aimed to identify more virus-selective inhibitors of NTCP by screening of 87 propanolamine derivatives from the former development of intestinal bile acid reabsorption inhibitors (BARIs), which interact with the NTCP-homologous intestinal apical sodium-dependent bile acid transporter (ASBT). Propanolamines 95-108 solute carrier family 10 member 2 Homo sapiens 304-308 33359100-1 2021 Apical sodium-dependent bile acid transporter (ASBT) catalyses uphill transport of bile acids using the electrochemical gradient of Na+ as the driving force. Bile Acids and Salts 83-93 solute carrier family 10 member 2 Homo sapiens 0-45 33189717-0 2021 S-acylation status of bile acid transporter hASBT regulates its function, metabolic stability, membrane expression, and phosphorylation state. Bile Acids and Salts 22-31 solute carrier family 10 member 2 Homo sapiens 44-49 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Sodium 17-23 solute carrier family 10 member 2 Homo sapiens 57-62 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Sodium 17-23 solute carrier family 10 member 2 Homo sapiens 64-71 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 57-62 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 64-71 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Bile Acids and Salts 113-122 solute carrier family 10 member 2 Homo sapiens 57-62 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Bile Acids and Salts 113-122 solute carrier family 10 member 2 Homo sapiens 64-71 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Bile Acids and Salts 177-187 solute carrier family 10 member 2 Homo sapiens 57-62 33189717-1 2021 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is the rate-limiting step of intestinal bile acid absorption in the enterohepatic circulation system of bile acids. Bile Acids and Salts 177-187 solute carrier family 10 member 2 Homo sapiens 64-71 33189717-2 2021 Therefore, the regulation and stability of hASBT is vital in maintaining bile acid and cholesterol homeostasis and may serve as a potential target for cholesterol-related disorders. Bile Acids and Salts 73-82 solute carrier family 10 member 2 Homo sapiens 43-48 33189717-2 2021 Therefore, the regulation and stability of hASBT is vital in maintaining bile acid and cholesterol homeostasis and may serve as a potential target for cholesterol-related disorders. Cholesterol 87-98 solute carrier family 10 member 2 Homo sapiens 43-48 33189717-2 2021 Therefore, the regulation and stability of hASBT is vital in maintaining bile acid and cholesterol homeostasis and may serve as a potential target for cholesterol-related disorders. Cholesterol 151-162 solute carrier family 10 member 2 Homo sapiens 43-48 33189717-3 2021 We hypothesized that post-translational mechanisms that govern hASBT function and regulation will provide novel insight on intestinal bile acid transport and homeostasis. Bile Acids and Salts 134-143 solute carrier family 10 member 2 Homo sapiens 63-68 33189717-4 2021 In this study, we confirm the S-acylation status of hASBT via acyl biotin exchange in COS-1 cells and its impact on hASBT expression, function, kinetics, and protein stability. acyl biotin 62-73 solute carrier family 10 member 2 Homo sapiens 52-57 33189717-5 2021 Using the acylation inhibitor, 2-bromopalmitate, we show that S-acylation is an important modification which modulates the function, surface expression, and maximal transporter flux (Jmax) of hASBT. 2-bromopalmitate 31-47 solute carrier family 10 member 2 Homo sapiens 192-197 33189717-8 2021 Lastly, we show that S-acylation was reduced in a mutant form of hASBT devoid of cytosolic facing tyrosine residues, suggestive of crosstalk between acylation and phosphorylation post-translational modification mechanisms. Tyrosine 98-106 solute carrier family 10 member 2 Homo sapiens 65-70 33359100-1 2021 Apical sodium-dependent bile acid transporter (ASBT) catalyses uphill transport of bile acids using the electrochemical gradient of Na+ as the driving force. Bile Acids and Salts 83-93 solute carrier family 10 member 2 Homo sapiens 47-51 32711025-2 2020 Apical sodium-dependent bile acid transporter (ASBT), an ileal Na+-dependent transporter, plays the leading role of bile acid absorption into enterocytes, where bile acids are delivered to basolateral side by ileal bile acid binding protein (IBABP) and then released by organic solute transporter OSTalpha/beta. Bile Acids and Salts 24-33 solute carrier family 10 member 2 Homo sapiens 47-51 32656959-7 2020 Luminal TDCA crossed the epithelial lining via the apical sodium-dependent BA transporter (ASBT) and its inhibitor, GSK2330672 significantly reduced luminal, but not basolateral TDCA activity. Phenobarbital 0-7 solute carrier family 10 member 2 Homo sapiens 51-89 32656959-7 2020 Luminal TDCA crossed the epithelial lining via the apical sodium-dependent BA transporter (ASBT) and its inhibitor, GSK2330672 significantly reduced luminal, but not basolateral TDCA activity. Phenobarbital 0-7 solute carrier family 10 member 2 Homo sapiens 91-95 32656959-7 2020 Luminal TDCA crossed the epithelial lining via the apical sodium-dependent BA transporter (ASBT) and its inhibitor, GSK2330672 significantly reduced luminal, but not basolateral TDCA activity. 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid 116-126 solute carrier family 10 member 2 Homo sapiens 51-89 32656959-7 2020 Luminal TDCA crossed the epithelial lining via the apical sodium-dependent BA transporter (ASBT) and its inhibitor, GSK2330672 significantly reduced luminal, but not basolateral TDCA activity. 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid 116-126 solute carrier family 10 member 2 Homo sapiens 91-95 32656959-7 2020 Luminal TDCA crossed the epithelial lining via the apical sodium-dependent BA transporter (ASBT) and its inhibitor, GSK2330672 significantly reduced luminal, but not basolateral TDCA activity. Phenobarbital 149-156 solute carrier family 10 member 2 Homo sapiens 51-89 32656959-7 2020 Luminal TDCA crossed the epithelial lining via the apical sodium-dependent BA transporter (ASBT) and its inhibitor, GSK2330672 significantly reduced luminal, but not basolateral TDCA activity. Phenobarbital 149-156 solute carrier family 10 member 2 Homo sapiens 91-95 32656959-11 2020 Furthermore, luminal-conjugated BAs require transport across the epithelium via ASBT in order to activate basolateral GPBA. Phenobarbital 13-20 solute carrier family 10 member 2 Homo sapiens 80-84 32711025-2 2020 Apical sodium-dependent bile acid transporter (ASBT), an ileal Na+-dependent transporter, plays the leading role of bile acid absorption into enterocytes, where bile acids are delivered to basolateral side by ileal bile acid binding protein (IBABP) and then released by organic solute transporter OSTalpha/beta. Bile Acids and Salts 161-171 solute carrier family 10 member 2 Homo sapiens 0-45 32711025-2 2020 Apical sodium-dependent bile acid transporter (ASBT), an ileal Na+-dependent transporter, plays the leading role of bile acid absorption into enterocytes, where bile acids are delivered to basolateral side by ileal bile acid binding protein (IBABP) and then released by organic solute transporter OSTalpha/beta. Bile Acids and Salts 161-171 solute carrier family 10 member 2 Homo sapiens 47-51 32711025-4 2020 In this process called "enterohepatic recycling", only 5% of the bile acid pool (~3 g in human) is excreted in feces, indicating the large recycling capacity and high transport efficacy of ASBT-mediated absorption. Bile Acids and Salts 65-74 solute carrier family 10 member 2 Homo sapiens 189-193 32711025-6 2020 This review introduces the key factors in enterohepatic recycling, especially the mechanism of bile acid uptake by ASBT, and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile acid-based prodrugs, bile acid/drug electrostatic complexation and bile acid-containing nanocarriers. Bile Acids and Salts 95-104 solute carrier family 10 member 2 Homo sapiens 115-119 32711025-6 2020 This review introduces the key factors in enterohepatic recycling, especially the mechanism of bile acid uptake by ASBT, and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile acid-based prodrugs, bile acid/drug electrostatic complexation and bile acid-containing nanocarriers. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 183-187 32711025-6 2020 This review introduces the key factors in enterohepatic recycling, especially the mechanism of bile acid uptake by ASBT, and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile acid-based prodrugs, bile acid/drug electrostatic complexation and bile acid-containing nanocarriers. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 183-187 32711025-6 2020 This review introduces the key factors in enterohepatic recycling, especially the mechanism of bile acid uptake by ASBT, and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile acid-based prodrugs, bile acid/drug electrostatic complexation and bile acid-containing nanocarriers. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 183-187 32711025-6 2020 This review introduces the key factors in enterohepatic recycling, especially the mechanism of bile acid uptake by ASBT, and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile acid-based prodrugs, bile acid/drug electrostatic complexation and bile acid-containing nanocarriers. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 183-187 32938201-4 2020 Recently, several studies have been published on ileal interruption of the enterohepatic circulation of bile acids, targeting the apical-sodium dependent bile acid transporter (ASBT, SLC10A2), as therapy for various diseases. Bile Acids and Salts 104-114 solute carrier family 10 member 2 Homo sapiens 130-175 32938201-4 2020 Recently, several studies have been published on ileal interruption of the enterohepatic circulation of bile acids, targeting the apical-sodium dependent bile acid transporter (ASBT, SLC10A2), as therapy for various diseases. Bile Acids and Salts 104-114 solute carrier family 10 member 2 Homo sapiens 177-181 32938201-4 2020 Recently, several studies have been published on ileal interruption of the enterohepatic circulation of bile acids, targeting the apical-sodium dependent bile acid transporter (ASBT, SLC10A2), as therapy for various diseases. Bile Acids and Salts 104-114 solute carrier family 10 member 2 Homo sapiens 183-190 32374492-3 2020 This pro-NTA, also called PBAM, is composed of an MIL-100 (Fe)-coated Prussian blue (PB) analogue (K2 Mn[Fe(CN)6 ]) with negligible absorption in the near-infrared region and spatial confinement of Mn2+ ions. pro-nta 5-12 solute carrier family 10 member 2 Homo sapiens 26-30 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 80-89 solute carrier family 10 member 2 Homo sapiens 103-107 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 80-89 solute carrier family 10 member 2 Homo sapiens 124-128 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 80-89 solute carrier family 10 member 2 Homo sapiens 178-185 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Sodium 137-143 solute carrier family 10 member 2 Homo sapiens 103-107 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Sodium 137-143 solute carrier family 10 member 2 Homo sapiens 124-128 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Sodium 137-143 solute carrier family 10 member 2 Homo sapiens 178-185 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 103-107 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 124-128 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 178-185 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 103-107 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 124-128 32653991-7 2020 This review explores the novel therapeutic concept of inhibiting the sole ileal bile acid transporter (IBAT), also known as ASBT (apical sodium-bile acid transporter, encoded by SLC10A2), as a means to reduce hepatic bile acid concentration after KPE. Bile Acids and Salts 144-153 solute carrier family 10 member 2 Homo sapiens 178-185 32653991-8 2020 By reducing return of bile acids to the cholestatic liver, IBAT inhibitors may potentially lessen or delay liver damage associated with the hepatotoxicity and cholangiopathy of bile acid accumulation. Bile Acids and Salts 22-32 solute carrier family 10 member 2 Homo sapiens 59-63 32653991-8 2020 By reducing return of bile acids to the cholestatic liver, IBAT inhibitors may potentially lessen or delay liver damage associated with the hepatotoxicity and cholangiopathy of bile acid accumulation. Bile Acids and Salts 22-31 solute carrier family 10 member 2 Homo sapiens 59-63 32653991-9 2020 The clinical programs of 2 IBAT inhibitors in development for the treatment of pediatric cholestatic liver diseases, maralixibat and odevixibat, are highlighted. Lopixibat 117-128 solute carrier family 10 member 2 Homo sapiens 27-31 32653991-9 2020 The clinical programs of 2 IBAT inhibitors in development for the treatment of pediatric cholestatic liver diseases, maralixibat and odevixibat, are highlighted. Odevixibat 133-143 solute carrier family 10 member 2 Homo sapiens 27-31 32201314-1 2020 Apical Sodium-dependent Bile Acid Transporter (ASBT) actively reabsorbs bile acids (BAs) from the gut lumen. Bile Acids and Salts 72-82 solute carrier family 10 member 2 Homo sapiens 0-45 32201314-1 2020 Apical Sodium-dependent Bile Acid Transporter (ASBT) actively reabsorbs bile acids (BAs) from the gut lumen. Bile Acids and Salts 72-82 solute carrier family 10 member 2 Homo sapiens 47-51 32201314-3 2020 Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. Cholesterol 96-107 solute carrier family 10 member 2 Homo sapiens 11-15 32201314-3 2020 Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. Glucose 119-126 solute carrier family 10 member 2 Homo sapiens 11-15 32201314-5 2020 In the past ten years, ASBT has been the focus by both academia and pharmaceutical industry as research targets not only for BA-related diseases but also for prodrug delivery. Bile Acids and Salts 125-127 solute carrier family 10 member 2 Homo sapiens 23-27 32595517-6 2020 Human IBD studies have shown that an inflamed ileum can interrupt enterohepatic recirculation of bile acid, which could be due to inflammatory cytokine induced repression of the ASBT promoter. Bile Acids and Salts 97-106 solute carrier family 10 member 2 Homo sapiens 178-182 32234329-1 2020 BCKGROUND & AIMS: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. volixibat 18-27 solute carrier family 10 member 2 Homo sapiens 51-96 32234329-1 2020 BCKGROUND & AIMS: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. volixibat 18-27 solute carrier family 10 member 2 Homo sapiens 98-102 32234329-1 2020 BCKGROUND & AIMS: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. Bile Acids and Salts 75-84 solute carrier family 10 member 2 Homo sapiens 98-102 32234329-1 2020 BCKGROUND & AIMS: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. Bile Acids and Salts 176-185 solute carrier family 10 member 2 Homo sapiens 51-96 32234329-1 2020 BCKGROUND & AIMS: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. Bile Acids and Salts 176-185 solute carrier family 10 member 2 Homo sapiens 98-102 32374492-3 2020 This pro-NTA, also called PBAM, is composed of an MIL-100 (Fe)-coated Prussian blue (PB) analogue (K2 Mn[Fe(CN)6 ]) with negligible absorption in the near-infrared region and spatial confinement of Mn2+ ions. mil-100 50-57 solute carrier family 10 member 2 Homo sapiens 26-30 32374492-3 2020 This pro-NTA, also called PBAM, is composed of an MIL-100 (Fe)-coated Prussian blue (PB) analogue (K2 Mn[Fe(CN)6 ]) with negligible absorption in the near-infrared region and spatial confinement of Mn2+ ions. Iron 59-61 solute carrier family 10 member 2 Homo sapiens 26-30 32374492-3 2020 This pro-NTA, also called PBAM, is composed of an MIL-100 (Fe)-coated Prussian blue (PB) analogue (K2 Mn[Fe(CN)6 ]) with negligible absorption in the near-infrared region and spatial confinement of Mn2+ ions. ferric ferrocyanide 70-83 solute carrier family 10 member 2 Homo sapiens 26-30 32374492-3 2020 This pro-NTA, also called PBAM, is composed of an MIL-100 (Fe)-coated Prussian blue (PB) analogue (K2 Mn[Fe(CN)6 ]) with negligible absorption in the near-infrared region and spatial confinement of Mn2+ ions. k2 mn 99-104 solute carrier family 10 member 2 Homo sapiens 26-30 32374492-3 2020 This pro-NTA, also called PBAM, is composed of an MIL-100 (Fe)-coated Prussian blue (PB) analogue (K2 Mn[Fe(CN)6 ]) with negligible absorption in the near-infrared region and spatial confinement of Mn2+ ions. fe(cn)6 105-112 solute carrier family 10 member 2 Homo sapiens 26-30 32374492-3 2020 This pro-NTA, also called PBAM, is composed of an MIL-100 (Fe)-coated Prussian blue (PB) analogue (K2 Mn[Fe(CN)6 ]) with negligible absorption in the near-infrared region and spatial confinement of Mn2+ ions. Manganese(2+) 198-202 solute carrier family 10 member 2 Homo sapiens 26-30 32374492-4 2020 In a mildly acidic tumor microenvironment (TME), PBAM can be specifically activated to synthesize the photothermal agent PB nanoparticles, with release of free Mn2+ ions due to the internal fast ion exchange, resulting in the "ON" state of both T1 -weighted magnetic resonance imaging and photoacoustic signals. Manganese(2+) 160-164 solute carrier family 10 member 2 Homo sapiens 49-53 31194565-0 2019 Tyrosine Phosphorylation Regulates Plasma Membrane Expression and Stability of the Human Bile Acid Transporter ASBT (SLC10A2). Tyrosine 0-8 solute carrier family 10 member 2 Homo sapiens 111-115 32588824-1 2020 Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT - ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. Bile Acids and Salts 42-51 solute carrier family 10 member 2 Homo sapiens 65-69 32588824-1 2020 Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT - ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. Bile Acids and Salts 42-51 solute carrier family 10 member 2 Homo sapiens 85-89 32588824-1 2020 Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT - ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. Bile Acids and Salts 42-51 solute carrier family 10 member 2 Homo sapiens 121-128 32588824-1 2020 Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT - ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. Bile Acids and Salts 186-196 solute carrier family 10 member 2 Homo sapiens 18-63 32588824-1 2020 Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT - ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. Bile Acids and Salts 186-196 solute carrier family 10 member 2 Homo sapiens 65-69 32588824-1 2020 Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT - ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. Bile Acids and Salts 186-196 solute carrier family 10 member 2 Homo sapiens 85-89 32588824-1 2020 Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT - ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. Bile Acids and Salts 186-196 solute carrier family 10 member 2 Homo sapiens 121-128 32162131-3 2020 An SLC10A2 gene mutation, which affects bile acid transport, was chosen as mutation of interest in this proof of concept study to attempt correction in human pluripotent haploid cells. Bile Acids and Salts 40-49 solute carrier family 10 member 2 Homo sapiens 3-10 32209977-2 2020 Apical sodium-dependent bile acid cotransporter (ASBT), a solute carrier membrane transport protein, transports bile acids. Bile Acids and Salts 112-122 solute carrier family 10 member 2 Homo sapiens 49-53 32209977-4 2020 Sodium taurocholate cotransporting polypeptide (NTCP), belonging to the same family as ASBT, has fluorescein 5(6)-isothiocyanate (FITC) and indocyanine green (ICG) transportability. Fluorescein-5-isothiocyanate 97-128 solute carrier family 10 member 2 Homo sapiens 87-91 32209977-4 2020 Sodium taurocholate cotransporting polypeptide (NTCP), belonging to the same family as ASBT, has fluorescein 5(6)-isothiocyanate (FITC) and indocyanine green (ICG) transportability. Fluorescein-5-isothiocyanate 130-134 solute carrier family 10 member 2 Homo sapiens 87-91 32209977-4 2020 Sodium taurocholate cotransporting polypeptide (NTCP), belonging to the same family as ASBT, has fluorescein 5(6)-isothiocyanate (FITC) and indocyanine green (ICG) transportability. Indocyanine Green 140-157 solute carrier family 10 member 2 Homo sapiens 87-91 32209977-4 2020 Sodium taurocholate cotransporting polypeptide (NTCP), belonging to the same family as ASBT, has fluorescein 5(6)-isothiocyanate (FITC) and indocyanine green (ICG) transportability. Indocyanine Green 159-162 solute carrier family 10 member 2 Homo sapiens 87-91 32035254-6 2020 The permeability of FLDP loaded STC/Soluplus SHNPs was STC dependent in the ileum, which was inhibited by the higher concentrations of STC and the inhibitor of apical sodium-dependent bile acid transporter (ASBT). Felodipine 20-24 solute carrier family 10 member 2 Homo sapiens 160-205 32035254-6 2020 The permeability of FLDP loaded STC/Soluplus SHNPs was STC dependent in the ileum, which was inhibited by the higher concentrations of STC and the inhibitor of apical sodium-dependent bile acid transporter (ASBT). Felodipine 20-24 solute carrier family 10 member 2 Homo sapiens 207-211 32035254-6 2020 The permeability of FLDP loaded STC/Soluplus SHNPs was STC dependent in the ileum, which was inhibited by the higher concentrations of STC and the inhibitor of apical sodium-dependent bile acid transporter (ASBT). polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 36-44 solute carrier family 10 member 2 Homo sapiens 160-205 32035254-6 2020 The permeability of FLDP loaded STC/Soluplus SHNPs was STC dependent in the ileum, which was inhibited by the higher concentrations of STC and the inhibitor of apical sodium-dependent bile acid transporter (ASBT). polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 36-44 solute carrier family 10 member 2 Homo sapiens 207-211 32035254-9 2020 In conclusion, STC/Soluplus SHNPs via ASBT are a potential strategy for enhancing the oral bioavailability of poorly water-soluble drugs. polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 19-27 solute carrier family 10 member 2 Homo sapiens 38-42 32071081-1 2020 The ileal apical sodium-dependent bile acid transporter (ASBT) is crucial for the enterohepatic circulation of bile acids. Bile Acids and Salts 111-121 solute carrier family 10 member 2 Homo sapiens 10-55 32071081-1 2020 The ileal apical sodium-dependent bile acid transporter (ASBT) is crucial for the enterohepatic circulation of bile acids. Bile Acids and Salts 111-121 solute carrier family 10 member 2 Homo sapiens 57-61 32071081-5 2020 Using the acyl resin-assisted capture (acyl-RAC) method, here we found that the majority of ASBT (~80%) was S-acylated in ileal brush border membrane vesicles from human organ donors, as well as in HEK293 cells stably transfected with ASBT (2BT cells). Acyl Coenzyme A 10-14 solute carrier family 10 member 2 Homo sapiens 92-96 32071081-5 2020 Using the acyl resin-assisted capture (acyl-RAC) method, here we found that the majority of ASBT (~80%) was S-acylated in ileal brush border membrane vesicles from human organ donors, as well as in HEK293 cells stably transfected with ASBT (2BT cells). Acyl Coenzyme A 39-43 solute carrier family 10 member 2 Homo sapiens 92-96 32071081-6 2020 Metabolic labeling with alkyne-palmitic acid (100 muM for 15 h) also showed that ASBT is S-acylated in 2BT cells. Alkynes 24-44 solute carrier family 10 member 2 Homo sapiens 81-85 32071081-7 2020 Incubation with the acyltransferase inhibitor 2-bromopalmitate (25 muM for 15 h) significantly reduced ASBT S-acylation, function, and levels on the plasma membrane. 2-bromopalmitate 46-62 solute carrier family 10 member 2 Homo sapiens 103-107 32071081-8 2020 Treatment of 2BT cells with saturated palmitic acid (100 muM for 15 h) increased ASBT function, whereas treatment with unsaturated oleic acid significantly reduced ASBT function. Palmitic Acid 38-51 solute carrier family 10 member 2 Homo sapiens 81-85 32071081-8 2020 Treatment of 2BT cells with saturated palmitic acid (100 muM for 15 h) increased ASBT function, whereas treatment with unsaturated oleic acid significantly reduced ASBT function. Oleic Acids 119-141 solute carrier family 10 member 2 Homo sapiens 164-168 32071081-9 2020 Metabolic labeling with alkyne-oleic acid (100 muM for 15 h) revealed that oleic acid attaches to ASBT, suggesting that unsaturated fatty acids may decrease ASBT"s function via a direct covalent interaction with ASBT. Fatty Acids, Unsaturated 120-143 solute carrier family 10 member 2 Homo sapiens 98-102 32071081-9 2020 Metabolic labeling with alkyne-oleic acid (100 muM for 15 h) revealed that oleic acid attaches to ASBT, suggesting that unsaturated fatty acids may decrease ASBT"s function via a direct covalent interaction with ASBT. Fatty Acids, Unsaturated 120-143 solute carrier family 10 member 2 Homo sapiens 157-161 32071081-9 2020 Metabolic labeling with alkyne-oleic acid (100 muM for 15 h) revealed that oleic acid attaches to ASBT, suggesting that unsaturated fatty acids may decrease ASBT"s function via a direct covalent interaction with ASBT. Fatty Acids, Unsaturated 120-143 solute carrier family 10 member 2 Homo sapiens 157-161 32071081-12 2020 These findings underscore the potential for unsaturated FAs to reduce ASBT function, which may be useful in disorders in which bile acid toxicity is implicated. Fatty Acids 56-59 solute carrier family 10 member 2 Homo sapiens 70-74 32071081-12 2020 These findings underscore the potential for unsaturated FAs to reduce ASBT function, which may be useful in disorders in which bile acid toxicity is implicated. Bile Acids and Salts 127-136 solute carrier family 10 member 2 Homo sapiens 70-74 32831234-4 2020 In contrast to some previously published reports, in the pure compound only one distinct phase was observed between Pbam PbZrO3-like antiferroelectric and Pm3m paraelectric phases. pbzro3 121-127 solute carrier family 10 member 2 Homo sapiens 116-120 31630179-7 2020 The glucose-lowering effects of ASBT inhibitors, bile acid sequestrants and metformin are at least partly mediated by modulation of bile acid circulation, which might allow an optimization of these bile acid modulating treatment modalities. Glucose 4-11 solute carrier family 10 member 2 Homo sapiens 32-36 31630179-7 2020 The glucose-lowering effects of ASBT inhibitors, bile acid sequestrants and metformin are at least partly mediated by modulation of bile acid circulation, which might allow an optimization of these bile acid modulating treatment modalities. Bile Acids and Salts 132-141 solute carrier family 10 member 2 Homo sapiens 32-36 31630179-7 2020 The glucose-lowering effects of ASBT inhibitors, bile acid sequestrants and metformin are at least partly mediated by modulation of bile acid circulation, which might allow an optimization of these bile acid modulating treatment modalities. Bile Acids and Salts 132-141 solute carrier family 10 member 2 Homo sapiens 32-36 31623375-4 2019 In the mammalian intestine, apical sodium-dependent bile acid cotransporter (ASBT; SLC10A2) is exclusively responsible for the reabsorption of bile acids in the terminal ileum. Sodium 35-41 solute carrier family 10 member 2 Homo sapiens 77-81 31623375-4 2019 In the mammalian intestine, apical sodium-dependent bile acid cotransporter (ASBT; SLC10A2) is exclusively responsible for the reabsorption of bile acids in the terminal ileum. Sodium 35-41 solute carrier family 10 member 2 Homo sapiens 83-90 31623375-4 2019 In the mammalian intestine, apical sodium-dependent bile acid cotransporter (ASBT; SLC10A2) is exclusively responsible for the reabsorption of bile acids in the terminal ileum. Bile Acids and Salts 52-61 solute carrier family 10 member 2 Homo sapiens 77-81 31623375-4 2019 In the mammalian intestine, apical sodium-dependent bile acid cotransporter (ASBT; SLC10A2) is exclusively responsible for the reabsorption of bile acids in the terminal ileum. Bile Acids and Salts 52-61 solute carrier family 10 member 2 Homo sapiens 83-90 31623375-4 2019 In the mammalian intestine, apical sodium-dependent bile acid cotransporter (ASBT; SLC10A2) is exclusively responsible for the reabsorption of bile acids in the terminal ileum. Bile Acids and Salts 143-153 solute carrier family 10 member 2 Homo sapiens 77-81 31623375-4 2019 In the mammalian intestine, apical sodium-dependent bile acid cotransporter (ASBT; SLC10A2) is exclusively responsible for the reabsorption of bile acids in the terminal ileum. Bile Acids and Salts 143-153 solute carrier family 10 member 2 Homo sapiens 83-90 31623375-9 2019 Moreover, enhanced FXR expression increased the expression of bile-acid-associated proteins (IBABP and OSTalpha) that are responsible for handling bile acids absorbed via ASBT in villus cells during obesity. Bile Acids and Salts 62-71 solute carrier family 10 member 2 Homo sapiens 171-175 31623375-9 2019 Moreover, enhanced FXR expression increased the expression of bile-acid-associated proteins (IBABP and OSTalpha) that are responsible for handling bile acids absorbed via ASBT in villus cells during obesity. Bile Acids and Salts 147-157 solute carrier family 10 member 2 Homo sapiens 171-175 31194565-0 2019 Tyrosine Phosphorylation Regulates Plasma Membrane Expression and Stability of the Human Bile Acid Transporter ASBT (SLC10A2). Tyrosine 0-8 solute carrier family 10 member 2 Homo sapiens 117-124 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Bile Acids and Salts 111-121 solute carrier family 10 member 2 Homo sapiens 57-62 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Bile Acids and Salts 111-121 solute carrier family 10 member 2 Homo sapiens 64-71 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 57-62 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 64-71 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Cholesterol 197-208 solute carrier family 10 member 2 Homo sapiens 57-62 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Cholesterol 197-208 solute carrier family 10 member 2 Homo sapiens 64-71 31194565-6 2019 Interestingly, PP2-mediated suppression of hASBT protein expression was rescued by the proteasome inhibitor MG132, suggesting that dephosphorylation impacts protein stability with the subsequent proteasome-dependent degradation of hASBT. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 108-113 solute carrier family 10 member 2 Homo sapiens 43-48 31194565-6 2019 Interestingly, PP2-mediated suppression of hASBT protein expression was rescued by the proteasome inhibitor MG132, suggesting that dephosphorylation impacts protein stability with the subsequent proteasome-dependent degradation of hASBT. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 108-113 solute carrier family 10 member 2 Homo sapiens 231-236 31194565-8 2019 Although all mutants had significantly altered hASBT function without changes in total cellular expression, sequential tyrosine mutations at the five residues above rendered hASBT nonfunctional with diminished protein expression. Tyrosine 119-127 solute carrier family 10 member 2 Homo sapiens 174-179 31194565-9 2019 Furthermore, orthovanadate-induced transport activity of single-point tyrosine mutants suggested a role for multiple tyrosine residues in the regulation of hASBT function and membrane expression. Vanadates 13-26 solute carrier family 10 member 2 Homo sapiens 156-161 31194565-9 2019 Furthermore, orthovanadate-induced transport activity of single-point tyrosine mutants suggested a role for multiple tyrosine residues in the regulation of hASBT function and membrane expression. Tyrosine 70-78 solute carrier family 10 member 2 Homo sapiens 156-161 31194565-9 2019 Furthermore, orthovanadate-induced transport activity of single-point tyrosine mutants suggested a role for multiple tyrosine residues in the regulation of hASBT function and membrane expression. Tyrosine 117-125 solute carrier family 10 member 2 Homo sapiens 156-161 31194565-10 2019 Overall, our data confirms that tyrosine phosphorylation mediated by Src family kinases (SFKs), in particular, regulates surface expression, function, and stability of hASBT. Tyrosine 32-40 solute carrier family 10 member 2 Homo sapiens 168-173 30573812-1 2019 The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na+-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. Bile Acids and Salts 31-33 solute carrier family 10 member 2 Homo sapiens 113-117 30573812-1 2019 The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na+-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. Bile Acids and Salts 31-33 solute carrier family 10 member 2 Homo sapiens 118-125 30573812-2 2019 We developed a novel ASBT inhibitor, an N-(3,4-o-dichlorophenyl)-2-(3-trifluoromethoxy) benzamide derivative referred to as IMB17-15, and investigated its therapeutic effects and the molecular mechanisms underlying the effects. n-(3,4-o-dichlorophenyl)-2-(3-trifluoromethoxy) benzamide 40-97 solute carrier family 10 member 2 Homo sapiens 21-25 30573812-0 2019 A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters. imb17-15 24-32 solute carrier family 10 member 2 Homo sapiens 8-12 30573812-10 2019 In conclusion, a novel ASBT inhibitor known as IMB17-15 protected hamsters against HFD-induced NFALD by manipulating BA and lipid homeostasis. Bile Acids and Salts 117-119 solute carrier family 10 member 2 Homo sapiens 23-27 30573812-1 2019 The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na+-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. Bile Acids and Salts 20-29 solute carrier family 10 member 2 Homo sapiens 113-117 30887569-4 2019 The first layered compounds in the corresponding ternary systems were discovered, Li0.9 Ge2.9 As3.1 and Li3 Si7 As8 , which crystallize in the Pbam (No. AS 8 112-115 solute carrier family 10 member 2 Homo sapiens 143-147 30573812-1 2019 The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na+-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. Bile Acids and Salts 20-29 solute carrier family 10 member 2 Homo sapiens 118-125 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 solute carrier family 10 member 2 Homo sapiens 103-110 30735608-1 2019 BACKGROUND AND AIMS: Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. Bile Acids and Salts 117-126 solute carrier family 10 member 2 Homo sapiens 140-144 30143751-17 2018 In vitro, UDCA decreases MC-histamine release, which was restored by blocking ASBT and FXRbeta. mc-histamine 25-37 solute carrier family 10 member 2 Homo sapiens 78-82 30735608-12 2019 CONCLUSIONS: Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. Bile Acids and Salts 114-123 solute carrier family 10 member 2 Homo sapiens 166-170 30867382-1 2019 Elobixibat is a novel small-molecule that acts as an inhibitor of the ileal bile acid transporter (IBAT), and used for chronic constipation in Japan. elobixibat 0-10 solute carrier family 10 member 2 Homo sapiens 99-103 31571170-5 2019 The role played by bile acid transport proteins (e.g., ASBT and OST-alpha/beta) is included in the discussion. Bile Acids and Salts 19-28 solute carrier family 10 member 2 Homo sapiens 55-59 30504769-4 2018 We demonstrate that lower bile acid transport by ASBT is accompanied by greater risk of gallstone disease and highlight the role of the intestinal compartment of the enterohepatic circulation of bile acids in gallstone disease susceptibility. Bile Acids and Salts 26-35 solute carrier family 10 member 2 Homo sapiens 49-53 30204504-3 2018 Elobixibat, a locally-acting ileal bile acid transporter (IBAT) inhibitor, leads to increased BA delivery to the colon and represents a new class of treatment for CC. Bile Acids and Salts 59-61 solute carrier family 10 member 2 Homo sapiens 29-56 30411915-4 2018 We uncover three low energy carbon polymorphs (Pbam-32, P6/mmm, and I4[over ]3d) with new topologies, containing 32, 36, and 94 atoms in their primitive cells, respectively. Carbon 28-34 solute carrier family 10 member 2 Homo sapiens 47-51 30411915-8 2018 Silicon, germanium, and tin versions of Pbam-32, P6/mmm, and I4[over ]3d also show energetic, dynamical, and mechanical stability. Silicon 0-7 solute carrier family 10 member 2 Homo sapiens 40-44 30411915-8 2018 Silicon, germanium, and tin versions of Pbam-32, P6/mmm, and I4[over ]3d also show energetic, dynamical, and mechanical stability. Tin 24-27 solute carrier family 10 member 2 Homo sapiens 40-44 30344125-2 2018 We sought to determine (1) whether abnormally increased blood BAs in liver cirrhotic patients with HE is caused by elevation of apical sodium-dependent BA transporter (ASBT)-mediated BA reabsorption; and (2) whether increased BA reabsorption would exacerbate ammonia-induced brain injuries. Bile Acids and Salts 62-64 solute carrier family 10 member 2 Homo sapiens 128-166 30344125-2 2018 We sought to determine (1) whether abnormally increased blood BAs in liver cirrhotic patients with HE is caused by elevation of apical sodium-dependent BA transporter (ASBT)-mediated BA reabsorption; and (2) whether increased BA reabsorption would exacerbate ammonia-induced brain injuries. Bile Acids and Salts 62-64 solute carrier family 10 member 2 Homo sapiens 168-172 30344125-2 2018 We sought to determine (1) whether abnormally increased blood BAs in liver cirrhotic patients with HE is caused by elevation of apical sodium-dependent BA transporter (ASBT)-mediated BA reabsorption; and (2) whether increased BA reabsorption would exacerbate ammonia-induced brain injuries. Bile Acids and Salts 152-154 solute carrier family 10 member 2 Homo sapiens 168-172 30204504-6 2018 Areas covered: Rationale for IBAT inhibitor in therapeutics, and preclinical and clinical pharmacology of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor. elobixibat 128-138 solute carrier family 10 member 2 Homo sapiens 29-33 30204504-6 2018 Areas covered: Rationale for IBAT inhibitor in therapeutics, and preclinical and clinical pharmacology of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor. elobixibat 128-138 solute carrier family 10 member 2 Homo sapiens 169-173 30186169-3 2018 The apical sodium-dependent bile acid transporter [ASBT; also known as ileal bile acid transporter (IBAT) and SLC10A2] is pivotal for the almost complete reabsorption of conjugated bile acids in the ileum. Bile Acids and Salts 181-191 solute carrier family 10 member 2 Homo sapiens 51-55 29927324-1 2018 Bile acid transporters, including the ileal apical sodium-dependent bile acid transporter (ASBT) and the hepatic sodium-taurocholate cotransporting polypeptide (NTCP), are crucial for the enterohepatic circulation of bile acids. Bile Acids and Salts 217-227 solute carrier family 10 member 2 Homo sapiens 44-89 29927324-1 2018 Bile acid transporters, including the ileal apical sodium-dependent bile acid transporter (ASBT) and the hepatic sodium-taurocholate cotransporting polypeptide (NTCP), are crucial for the enterohepatic circulation of bile acids. Bile Acids and Salts 217-227 solute carrier family 10 member 2 Homo sapiens 91-95 30062877-2 2018 In the paramagnetic region at room temperature, the compound adopts the crystal structure first reported for Sr2Co3S2O3, crystallizing in space group Pbam with a = 7.8121 A, b = 10.2375 A, c = 3.9939 A, and Z = 2. sr2co3s2o3 109-119 solute carrier family 10 member 2 Homo sapiens 150-154 30024587-4 2018 An arylboronic ester (BE)-modified amphiphilic copolymer (mPEG-PBAM) was designed to form micelles and encapsulate doxorubicin (Dox) and hematoporphyrin (Hp). arylboronic ester 3-20 solute carrier family 10 member 2 Homo sapiens 63-67 30024587-4 2018 An arylboronic ester (BE)-modified amphiphilic copolymer (mPEG-PBAM) was designed to form micelles and encapsulate doxorubicin (Dox) and hematoporphyrin (Hp). Beryllium 22-24 solute carrier family 10 member 2 Homo sapiens 63-67 30024587-4 2018 An arylboronic ester (BE)-modified amphiphilic copolymer (mPEG-PBAM) was designed to form micelles and encapsulate doxorubicin (Dox) and hematoporphyrin (Hp). copolymer 47-56 solute carrier family 10 member 2 Homo sapiens 63-67 30024587-4 2018 An arylboronic ester (BE)-modified amphiphilic copolymer (mPEG-PBAM) was designed to form micelles and encapsulate doxorubicin (Dox) and hematoporphyrin (Hp). Doxorubicin 115-126 solute carrier family 10 member 2 Homo sapiens 63-67 30024587-4 2018 An arylboronic ester (BE)-modified amphiphilic copolymer (mPEG-PBAM) was designed to form micelles and encapsulate doxorubicin (Dox) and hematoporphyrin (Hp). Doxorubicin 128-131 solute carrier family 10 member 2 Homo sapiens 63-67 30024587-4 2018 An arylboronic ester (BE)-modified amphiphilic copolymer (mPEG-PBAM) was designed to form micelles and encapsulate doxorubicin (Dox) and hematoporphyrin (Hp). Hematoporphyrins 137-152 solute carrier family 10 member 2 Homo sapiens 63-67 30024587-4 2018 An arylboronic ester (BE)-modified amphiphilic copolymer (mPEG-PBAM) was designed to form micelles and encapsulate doxorubicin (Dox) and hematoporphyrin (Hp). Hematoporphyrins 154-156 solute carrier family 10 member 2 Homo sapiens 63-67 29927324-6 2018 Coincubation of CA-SS-Luc with natural bile acids enhanced the bioluminescence in a concentration-dependent manner with kinetic parameters for ASBT similar to those previously reported using conventional methods. Bile Acids and Salts 39-49 solute carrier family 10 member 2 Homo sapiens 143-147 30186169-3 2018 The apical sodium-dependent bile acid transporter [ASBT; also known as ileal bile acid transporter (IBAT) and SLC10A2] is pivotal for the almost complete reabsorption of conjugated bile acids in the ileum. Bile Acids and Salts 181-191 solute carrier family 10 member 2 Homo sapiens 71-98 30186169-3 2018 The apical sodium-dependent bile acid transporter [ASBT; also known as ileal bile acid transporter (IBAT) and SLC10A2] is pivotal for the almost complete reabsorption of conjugated bile acids in the ileum. Bile Acids and Salts 181-191 solute carrier family 10 member 2 Homo sapiens 100-104 30186169-3 2018 The apical sodium-dependent bile acid transporter [ASBT; also known as ileal bile acid transporter (IBAT) and SLC10A2] is pivotal for the almost complete reabsorption of conjugated bile acids in the ileum. Bile Acids and Salts 181-191 solute carrier family 10 member 2 Homo sapiens 110-117 30186169-5 2018 Pharmacological IBAT inhibition results in an increased bile acid load in the colon and subsequently a lower bile acid pool, which is associated with improved liver histology in animal models of cholestatic liver disease and non-alcoholic steatohepatitis (NASH). Bile Acids and Salts 56-65 solute carrier family 10 member 2 Homo sapiens 16-20 30186169-5 2018 Pharmacological IBAT inhibition results in an increased bile acid load in the colon and subsequently a lower bile acid pool, which is associated with improved liver histology in animal models of cholestatic liver disease and non-alcoholic steatohepatitis (NASH). Bile Acids and Salts 109-118 solute carrier family 10 member 2 Homo sapiens 16-20 28898457-2 2018 Mutations in the ileal apical sodium-dependent bile acid transporter (ASBT; SLC10A2) can cause primary bile acid malabsorption but do not appear to account for most familial cases. Bile Acids and Salts 47-56 solute carrier family 10 member 2 Homo sapiens 70-74 28898457-2 2018 Mutations in the ileal apical sodium-dependent bile acid transporter (ASBT; SLC10A2) can cause primary bile acid malabsorption but do not appear to account for most familial cases. Bile Acids and Salts 47-56 solute carrier family 10 member 2 Homo sapiens 76-83 29642873-0 2018 Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway. Bexarotene 0-10 solute carrier family 10 member 2 Homo sapiens 74-81 29704003-0 2018 Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Odevixibat 32-37 solute carrier family 10 member 2 Homo sapiens 17-21 29704003-2 2018 Inhibition of the ileal bile acid transporter (IBAT/ASBT) may emerge as treatment option. Bile Acids and Salts 24-33 solute carrier family 10 member 2 Homo sapiens 47-51 29704003-2 2018 Inhibition of the ileal bile acid transporter (IBAT/ASBT) may emerge as treatment option. Bile Acids and Salts 24-33 solute carrier family 10 member 2 Homo sapiens 52-56 29704003-3 2018 Our aim was to assess tolerability and effect on pruritus of the selective IBAT inhibitor A4250 in patients with primary biliary cholangitis (PBC). Odevixibat 90-95 solute carrier family 10 member 2 Homo sapiens 75-79 30129377-0 2018 Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation. elobixibat 0-10 solute carrier family 10 member 2 Homo sapiens 31-58 30129377-2 2018 IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon. Bile Acids and Salts 42-52 solute carrier family 10 member 2 Homo sapiens 0-4 30129377-2 2018 IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon. Cholesterol 141-152 solute carrier family 10 member 2 Homo sapiens 0-4 30129377-2 2018 IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon. Bile Acids and Salts 188-198 solute carrier family 10 member 2 Homo sapiens 0-4 30129377-8 2018 Expert opinion: The early phases of elobixibat development provide confirmation of high IBAT binding affinity which translates into the expected inhibition of enterohepatic bile acid circulation and enhanced delivery of ileal bile acids to the colon associated with expected physiological changes. Bile Acids and Salts 173-182 solute carrier family 10 member 2 Homo sapiens 88-92 30129377-8 2018 Expert opinion: The early phases of elobixibat development provide confirmation of high IBAT binding affinity which translates into the expected inhibition of enterohepatic bile acid circulation and enhanced delivery of ileal bile acids to the colon associated with expected physiological changes. Bile Acids and Salts 226-236 solute carrier family 10 member 2 Homo sapiens 88-92 29642873-8 2018 In addition, overexpressed slc10a2 in NSCLC cells can further suppress the proliferation and migration, and promote apoptosis under the treatment of bexarotene. Bexarotene 149-159 solute carrier family 10 member 2 Homo sapiens 27-34 29642873-9 2018 On the contrary, the opposite results were obtained after slc10a2 gene was silenced in NSCLC cells treated with bexarotene. Bexarotene 112-122 solute carrier family 10 member 2 Homo sapiens 58-65 29642873-12 2018 CONCLUSION: These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway. Bexarotene 39-49 solute carrier family 10 member 2 Homo sapiens 98-105 29513527-4 2018 Li2Zn(SeO3)2 crystallizes in the orthorhombic space group Pbam and reveals a layered structure in the bc plane. li2zn(seo3)2 0-12 solute carrier family 10 member 2 Homo sapiens 58-62 29319707-3 2018 LVBO crystallizes in the space group Pbam with V atom and Li atom occupying the same sites, which makes the structure more stable and brings a disorder effect. Vanadium 1-2 solute carrier family 10 member 2 Homo sapiens 37-41 29304731-0 2018 Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. volixibat 107-116 solute carrier family 10 member 2 Homo sapiens 45-90 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 117-128 solute carrier family 10 member 2 Homo sapiens 0-45 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 117-128 solute carrier family 10 member 2 Homo sapiens 47-51 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Bile Acids and Salts 173-183 solute carrier family 10 member 2 Homo sapiens 0-45 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Bile Acids and Salts 173-183 solute carrier family 10 member 2 Homo sapiens 47-51 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Bile Acids and Salts 185-187 solute carrier family 10 member 2 Homo sapiens 0-45 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Bile Acids and Salts 185-187 solute carrier family 10 member 2 Homo sapiens 47-51 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 246-257 solute carrier family 10 member 2 Homo sapiens 0-45 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 246-257 solute carrier family 10 member 2 Homo sapiens 47-51 29304731-3 2018 The aim of this phase 1 study in adult healthy volunteers (HVs) and patients with type 2 diabetes mellitus (T2DM) was to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ASBT inhibition with volixibat (SHP626; formerly LUM002). volixibat 216-225 solute carrier family 10 member 2 Homo sapiens 195-199 29198943-1 2018 The human apical sodium-dependent bile acid transporter, hASBT/SLC10A2, plays a central role in cholesterol homeostasis via the efficient reabsorption of bile acids from the distal ileum. Cholesterol 96-107 solute carrier family 10 member 2 Homo sapiens 57-62 29198943-1 2018 The human apical sodium-dependent bile acid transporter, hASBT/SLC10A2, plays a central role in cholesterol homeostasis via the efficient reabsorption of bile acids from the distal ileum. Cholesterol 96-107 solute carrier family 10 member 2 Homo sapiens 63-70 29198943-1 2018 The human apical sodium-dependent bile acid transporter, hASBT/SLC10A2, plays a central role in cholesterol homeostasis via the efficient reabsorption of bile acids from the distal ileum. Bile Acids and Salts 154-164 solute carrier family 10 member 2 Homo sapiens 57-62 29198943-1 2018 The human apical sodium-dependent bile acid transporter, hASBT/SLC10A2, plays a central role in cholesterol homeostasis via the efficient reabsorption of bile acids from the distal ileum. Bile Acids and Salts 154-164 solute carrier family 10 member 2 Homo sapiens 63-70 29198943-4 2018 We generated a cysteine-less form of hASBT by creating point mutations at all 13 endogenous cysteines in a stepwise manner. Cysteine 15-23 solute carrier family 10 member 2 Homo sapiens 37-42 29198943-4 2018 We generated a cysteine-less form of hASBT by creating point mutations at all 13 endogenous cysteines in a stepwise manner. Cysteine 92-101 solute carrier family 10 member 2 Homo sapiens 37-42 29355315-6 2018 The tomatoside A-induced reduction in glucose transport was restored in cells treated with apical sodium-dependent bile acid transporter (ASBT) siRNA or an ASBT antagonist. Tomatoside A 4-16 solute carrier family 10 member 2 Homo sapiens 91-136 29355315-6 2018 The tomatoside A-induced reduction in glucose transport was restored in cells treated with apical sodium-dependent bile acid transporter (ASBT) siRNA or an ASBT antagonist. Tomatoside A 4-16 solute carrier family 10 member 2 Homo sapiens 138-142 29355315-6 2018 The tomatoside A-induced reduction in glucose transport was restored in cells treated with apical sodium-dependent bile acid transporter (ASBT) siRNA or an ASBT antagonist. Tomatoside A 4-16 solute carrier family 10 member 2 Homo sapiens 156-160 29355315-6 2018 The tomatoside A-induced reduction in glucose transport was restored in cells treated with apical sodium-dependent bile acid transporter (ASBT) siRNA or an ASBT antagonist. Glucose 38-45 solute carrier family 10 member 2 Homo sapiens 91-136 29355315-6 2018 The tomatoside A-induced reduction in glucose transport was restored in cells treated with apical sodium-dependent bile acid transporter (ASBT) siRNA or an ASBT antagonist. Glucose 38-45 solute carrier family 10 member 2 Homo sapiens 138-142 29355315-6 2018 The tomatoside A-induced reduction in glucose transport was restored in cells treated with apical sodium-dependent bile acid transporter (ASBT) siRNA or an ASBT antagonist. Glucose 38-45 solute carrier family 10 member 2 Homo sapiens 156-160 29355315-7 2018 These findings demonstrated for the first time that the nontransportable tomato seed steroidal saponin, tomatoside A, suppressed GLUT2 expression via PKC signaling pathway during the ASBT-influx/MRP2-efflux process in Caco-2 cells. Saponins 95-102 solute carrier family 10 member 2 Homo sapiens 183-187 29355315-7 2018 These findings demonstrated for the first time that the nontransportable tomato seed steroidal saponin, tomatoside A, suppressed GLUT2 expression via PKC signaling pathway during the ASBT-influx/MRP2-efflux process in Caco-2 cells. Tomatoside A 104-116 solute carrier family 10 member 2 Homo sapiens 183-187 29055774-5 2018 In Caco-2 cell monolayers, DNPs are internalized via apical sodium-dependent bile acid transporter (ASBT)-mediated endocytosis. dnps 27-31 solute carrier family 10 member 2 Homo sapiens 53-98 29055774-5 2018 In Caco-2 cell monolayers, DNPs are internalized via apical sodium-dependent bile acid transporter (ASBT)-mediated endocytosis. dnps 27-31 solute carrier family 10 member 2 Homo sapiens 100-104 28972740-2 2017 Both compounds are isostructural to the compound Sr2Co3S2O3 (space group Pbam), which contains a novel hybrid spin ladder: a combination of a 2-leg rectangular ladder and a necklace ladder. sr2co3s2o3 49-59 solute carrier family 10 member 2 Homo sapiens 73-77 28336180-0 2017 An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT). Bile Acids and Salts 84-94 solute carrier family 10 member 2 Homo sapiens 175-182 28336180-0 2017 An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT). Bile Acids and Salts 84-94 solute carrier family 10 member 2 Homo sapiens 183-187 28336180-0 2017 An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT). Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 175-182 28336180-0 2017 An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT). Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 183-187 28336180-3 2017 Previous studies revealed that regulation of the ASBT involves BAs and cholesterol. Cholesterol 71-82 solute carrier family 10 member 2 Homo sapiens 49-53 28336180-4 2017 In addition, abnormal ASBT expression and function might lead to some diseases associated with disorders in the enterohepatic circulation of BAs and cholesterol homeostasis, such as diarrhoea and gallstones. Cholesterol 149-160 solute carrier family 10 member 2 Homo sapiens 22-26 28336180-5 2017 However, decreasing cholesterol or BAs by partly inhibiting ASBT-mediated transport might be used for treatments of hypercholesterolemia, cholestasis and diabetes. Cholesterol 20-31 solute carrier family 10 member 2 Homo sapiens 60-64 28336180-6 2017 This review mainly discusses the regulation of the ASBT by BAs and cholesterol and its relevance to diseases and treatment. Cholesterol 67-78 solute carrier family 10 member 2 Homo sapiens 51-55 28819401-10 2017 Analyses of two open source, RNA expression data sets on sunitinib response revealed that SLC10A2 was downregulated in tyrosine kinase inhibitor-resistant samples. Sunitinib 57-66 solute carrier family 10 member 2 Homo sapiens 90-97 29979499-2 2017 The ilealapical sodium-dependent bile acid transporter (ASBT) located at the enterocyte brush border is responsible forthe reuptake of bile acids and the maintenance of bile acid homeostasis. Bile Acids and Salts 135-145 solute carrier family 10 member 2 Homo sapiens 56-60 28013215-5 2017 Furthermore, we demonstrated that the human apical sodium-dependent bile salt transporter (ASBT) contributes to the intestinal reabsorption of PFOS. perfluorooctane sulfonic acid 143-147 solute carrier family 10 member 2 Homo sapiens 44-89 28013215-5 2017 Furthermore, we demonstrated that the human apical sodium-dependent bile salt transporter (ASBT) contributes to the intestinal reabsorption of PFOS. perfluorooctane sulfonic acid 143-147 solute carrier family 10 member 2 Homo sapiens 91-95 28303230-1 2017 The apical sodium--dependent bile acid transporter (ASBT) is the main transporter to promote re-absorption of bile acids from the intestinal tract into the enterohepatic circulation. Bile Acids and Salts 110-120 solute carrier family 10 member 2 Homo sapiens 4-50 28303230-1 2017 The apical sodium--dependent bile acid transporter (ASBT) is the main transporter to promote re-absorption of bile acids from the intestinal tract into the enterohepatic circulation. Bile Acids and Salts 110-120 solute carrier family 10 member 2 Homo sapiens 52-56 28303230-2 2017 Inhibition of ASBT could increase the excretion of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Bile Acids and Salts 51-61 solute carrier family 10 member 2 Homo sapiens 14-18 28303230-2 2017 Inhibition of ASBT could increase the excretion of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Bile Acids and Salts 51-60 solute carrier family 10 member 2 Homo sapiens 14-18 28303230-2 2017 Inhibition of ASBT could increase the excretion of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Cholesterol 116-127 solute carrier family 10 member 2 Homo sapiens 14-18 28303230-3 2017 Therefore, ASBT is an attractive target for developing new cholesterol-lowering drugs. Cholesterol 59-70 solute carrier family 10 member 2 Homo sapiens 11-15 28303230-4 2017 In this report, a series of 1-(2,4-bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides were designed as inhibitors of ASBT. 1-(2,4-bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides 28-98 solute carrier family 10 member 2 Homo sapiens 130-134 28303230-5 2017 Most of them demonstrated potency against ASBT transport of bile acids. Bile Acids and Salts 60-70 solute carrier family 10 member 2 Homo sapiens 42-46 29979499-2 2017 The ilealapical sodium-dependent bile acid transporter (ASBT) located at the enterocyte brush border is responsible forthe reuptake of bile acids and the maintenance of bile acid homeostasis. Bile Acids and Salts 33-42 solute carrier family 10 member 2 Homo sapiens 56-60 26661379-2 2016 The crystal structure of Bi2Fe3CrO9 was investigated using X-ray and neutron powder diffraction, transmission electron microscopy and (57)Fe Mossbauer spectroscopy (S.G. Pbam, a = 7.95579(9) A, b = 8.39145(9) A, c = 5.98242(7) A, RF(X-ray) = 0.022, RF(neutron) = 0.057). bi2fe3cro9 25-35 solute carrier family 10 member 2 Homo sapiens 170-174 28249258-2 2017 The apical sodium-dependent transporter (ASBT) protein located in the terminal ileum plays an important physiological role in the enterohepatic circulation of BAs and therefore essential for the BA homeostasis. Bile Acids and Salts 159-161 solute carrier family 10 member 2 Homo sapiens 41-45 28249269-0 2017 Roles of Ileal ASBT and OSTalpha-OSTbeta in Regulating Bile Acid Signaling. Bile Acids and Salts 55-64 solute carrier family 10 member 2 Homo sapiens 15-19 28249269-5 2017 CONCLUSIONS: Dysregulated expression of the Asbt and Ostalpha-Ostbeta alters bile acid signaling via the gut-liver farnesoid X receptor-fibroblast growth factor 15/19 axis and may contribute to other bile acid-regulated metabolic and cell injury pathways. Bile Acids and Salts 77-86 solute carrier family 10 member 2 Homo sapiens 44-48 28249269-5 2017 CONCLUSIONS: Dysregulated expression of the Asbt and Ostalpha-Ostbeta alters bile acid signaling via the gut-liver farnesoid X receptor-fibroblast growth factor 15/19 axis and may contribute to other bile acid-regulated metabolic and cell injury pathways. Bile Acids and Salts 200-209 solute carrier family 10 member 2 Homo sapiens 44-48 28249291-2 2017 The sodium taurocholate cotransporting polypeptide (NTCP) and the apical sodium dependent bile acid transporter (ASBT) ensure an effective circulation of (conjugated) bile acids. Bile Acids and Salts 167-177 solute carrier family 10 member 2 Homo sapiens 66-111 28249291-2 2017 The sodium taurocholate cotransporting polypeptide (NTCP) and the apical sodium dependent bile acid transporter (ASBT) ensure an effective circulation of (conjugated) bile acids. Bile Acids and Salts 167-177 solute carrier family 10 member 2 Homo sapiens 113-117 28249291-5 2017 Multiple ASBT-inhibitors are already in clinical trials to inhibit intestinal bile acid uptake. Bile Acids and Salts 78-87 solute carrier family 10 member 2 Homo sapiens 9-13 27834485-1 2016 The H blood group system, ISBT symbol H (018), consists of a single antigen (H) defined by a terminal fucose residue found on red blood cells and in secretions formed by the action of alpha-1,2-fucosyltransferases 1 (alpha2FucT1) and 2 (alpha2FucT2), respectively. Fucose 102-108 solute carrier family 10 member 2 Homo sapiens 26-30 27431238-4 2016 Pharmacological inhibition of IBAT with GSK2330672 may reduce BA levels in the systemic circulation and improve pruritus. 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid 40-50 solute carrier family 10 member 2 Homo sapiens 30-34 25619609-3 2015 (CuCl)PrNb(2)O(7), topochemically prepared by replacement of Rb(+)/Cs(+) with CuCl(+), contains a 2D Cu-Cl network between the PrNb(2)O(7) slabs (orthorhombic space group Pbam, a = 7.7328(6) A, b = 7.7113(4) A and c = 11.6706(3) A). cuprous chloride 1-5 solute carrier family 10 member 2 Homo sapiens 171-175 26001962-5 2015 Given that the Na(+)/taurocholate cotransporting polypeptide (NTCP) and the apical sodium-dependent bile salt transporter (ASBT) are essential for the enterohepatic circulation of bile acids, transport of PFASs was investigated in stable CHO Flp-In cells for human NTCP or HEK293 cells transiently expressing rat NTCP, human ASBT, and rat ASBT. Bile Acids and Salts 180-190 solute carrier family 10 member 2 Homo sapiens 325-329 26001962-9 2015 Only PFOS was transported by human ASBT whereas rat ASBT did not transport any of the tested PFASs. perfluorooctane sulfonic acid 5-9 solute carrier family 10 member 2 Homo sapiens 35-39 26001962-11 2015 In conclusion, these results suggest that the long half-live and the hepatic accumulation of PFOS in humans are at least, in part, due to transport by NTCP and ASBT. perfluorooctane sulfonic acid 93-97 solute carrier family 10 member 2 Homo sapiens 160-164 26086474-2 2015 In recent years, small bile acid analogues have been developed for the purpose of apical sodium-dependent bile acid transporter (ASBT) inhibition. Bile Acids and Salts 23-32 solute carrier family 10 member 2 Homo sapiens 82-127 26086474-2 2015 In recent years, small bile acid analogues have been developed for the purpose of apical sodium-dependent bile acid transporter (ASBT) inhibition. Bile Acids and Salts 23-32 solute carrier family 10 member 2 Homo sapiens 129-133 26086474-3 2015 Here, we designed a novel hydrophilic ASBT inhibitor using oligomeric bile acid with a high affinity with ASBT. Bile Acids and Salts 70-79 solute carrier family 10 member 2 Homo sapiens 38-42 26086474-3 2015 Here, we designed a novel hydrophilic ASBT inhibitor using oligomeric bile acid with a high affinity with ASBT. Bile Acids and Salts 70-79 solute carrier family 10 member 2 Homo sapiens 106-110 26086474-4 2015 Polyacrylic acid-tetraDOCA conjugates (PATD) have the ability to bind to ASBT in order to induce hypocholesterolemic effects. carbopol 940 0-16 solute carrier family 10 member 2 Homo sapiens 73-77 25855079-0 2015 N-glycosylation is essential for ileal ASBT function and protection against proteases. Nitrogen 0-1 solute carrier family 10 member 2 Homo sapiens 39-43 25855079-1 2015 The bile acid transporter ASBT is a glycoprotein responsible for active absorption of bile acids. Bile Acids and Salts 86-96 solute carrier family 10 member 2 Homo sapiens 26-30 25855079-2 2015 Inhibiting ASBT function and bile acid absorption is an attractive approach to lower plasma cholesterol and improve glucose imbalance in diabetic patients. Cholesterol 92-103 solute carrier family 10 member 2 Homo sapiens 11-15 25855079-2 2015 Inhibiting ASBT function and bile acid absorption is an attractive approach to lower plasma cholesterol and improve glucose imbalance in diabetic patients. Glucose 116-123 solute carrier family 10 member 2 Homo sapiens 11-15 25855079-4 2015 However, the exact roles of N-glycosylation of ASBT, and how it affects its function, is not known. Nitrogen 28-29 solute carrier family 10 member 2 Homo sapiens 47-51 25855079-7 2015 Inhibition of glycosylation by tunicamycin significantly decreased ASBT activity and shifted ASBT bands to ~30 kDa, representing a deglycosylated protein. Tunicamycin 31-42 solute carrier family 10 member 2 Homo sapiens 67-71 25855079-7 2015 Inhibition of glycosylation by tunicamycin significantly decreased ASBT activity and shifted ASBT bands to ~30 kDa, representing a deglycosylated protein. Tunicamycin 31-42 solute carrier family 10 member 2 Homo sapiens 93-97 25855079-9 2015 Studies with the glycosylation deficient ASBT mutant (N10Q) showed that the N-glycosylation is not essential for ASBT targeting to plasma membrane. Nitrogen 54-55 solute carrier family 10 member 2 Homo sapiens 41-45 25855079-11 2015 Incubating the cells with high glucose (25 mM) for 48 h increased mature glycosylated ASBT along with an increase in its function. Glucose 31-38 solute carrier family 10 member 2 Homo sapiens 86-90 25855079-12 2015 These results unravel novel roles for N-glycosylation of ASBT and suggest that high levels of glucose alter the composition of the glycan and may contribute to the increase in ASBT function in diabetes mellitus. Nitrogen 38-39 solute carrier family 10 member 2 Homo sapiens 57-61 25855079-12 2015 These results unravel novel roles for N-glycosylation of ASBT and suggest that high levels of glucose alter the composition of the glycan and may contribute to the increase in ASBT function in diabetes mellitus. Glucose 94-101 solute carrier family 10 member 2 Homo sapiens 176-180 25855079-12 2015 These results unravel novel roles for N-glycosylation of ASBT and suggest that high levels of glucose alter the composition of the glycan and may contribute to the increase in ASBT function in diabetes mellitus. Polysaccharides 131-137 solute carrier family 10 member 2 Homo sapiens 176-180 24498857-0 2014 Resveratrol promotes degradation of the human bile acid transporter ASBT (SLC10A2). Resveratrol 0-11 solute carrier family 10 member 2 Homo sapiens 68-72 25239307-7 2014 Bile salt uptake by the apical sodium-dependent bile salt transporter solute carrier family 10 (sodium/bile acid cotransporter), member 2 (SLC10A2) was strongly impaired in ATP8B1-depleted Caco-2 cells. Bile Acids and Salts 0-9 solute carrier family 10 member 2 Homo sapiens 139-146 25466967-4 2015 Affinity of TC to the uptake transporters OATP1A2, -1B1, -1B3, -2B1, OCT1, -2, -3, OCTN2, NTCP, and ASBT and the efflux carriers P-gp, MRP2 and MRP3 transfected in HEK293 and MDCK2 cells was measured. trospium chloride 12-14 solute carrier family 10 member 2 Homo sapiens 100-104 24498857-0 2014 Resveratrol promotes degradation of the human bile acid transporter ASBT (SLC10A2). Resveratrol 0-11 solute carrier family 10 member 2 Homo sapiens 74-81 24498857-1 2014 The sodium/bile acid co-transporter ASBT [apical sodium-dependent bile acid transporter; SLC10A2 (solute carrier family 10 member 2)] plays a key role in the enterohepatic recycling of the bile acids and indirectly contributes to cholesterol homoeostasis. Bile Acids and Salts 189-199 solute carrier family 10 member 2 Homo sapiens 36-40 24498857-1 2014 The sodium/bile acid co-transporter ASBT [apical sodium-dependent bile acid transporter; SLC10A2 (solute carrier family 10 member 2)] plays a key role in the enterohepatic recycling of the bile acids and indirectly contributes to cholesterol homoeostasis. Bile Acids and Salts 189-199 solute carrier family 10 member 2 Homo sapiens 89-96 24498857-1 2014 The sodium/bile acid co-transporter ASBT [apical sodium-dependent bile acid transporter; SLC10A2 (solute carrier family 10 member 2)] plays a key role in the enterohepatic recycling of the bile acids and indirectly contributes to cholesterol homoeostasis. Bile Acids and Salts 189-199 solute carrier family 10 member 2 Homo sapiens 98-131 24498857-2 2014 ASBT inhibitors reportedly lower plasma triglyceride levels and increase HDL (high-density lipoprotein) cholesterol levels. Triglycerides 40-52 solute carrier family 10 member 2 Homo sapiens 0-4 24498857-2 2014 ASBT inhibitors reportedly lower plasma triglyceride levels and increase HDL (high-density lipoprotein) cholesterol levels. Cholesterol 104-115 solute carrier family 10 member 2 Homo sapiens 0-4 24498857-4 2014 In the present study, we investigated the possible involvement of ASBT in RSV-mediated cholesterol-lowering effects. Resveratrol 74-77 solute carrier family 10 member 2 Homo sapiens 66-70 24498857-4 2014 In the present study, we investigated the possible involvement of ASBT in RSV-mediated cholesterol-lowering effects. Cholesterol 87-98 solute carrier family 10 member 2 Homo sapiens 66-70 24498857-5 2014 We demonstrate that RSV inhibits ASBT protein expression and function via a SIRT1 (sirtuin 1)-independent mechanism. Resveratrol 20-23 solute carrier family 10 member 2 Homo sapiens 33-37 24498857-7 2014 ASBT inhibition by RSV was reversed by proteasome inhibitors (MG-132 and lactacystin) and the ubiquitin inhibitor LDN57444, suggesting involvement of the ubiquitin-proteasome pathway. Resveratrol 19-22 solute carrier family 10 member 2 Homo sapiens 0-4 24498857-7 2014 ASBT inhibition by RSV was reversed by proteasome inhibitors (MG-132 and lactacystin) and the ubiquitin inhibitor LDN57444, suggesting involvement of the ubiquitin-proteasome pathway. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 62-68 solute carrier family 10 member 2 Homo sapiens 0-4 24498857-7 2014 ASBT inhibition by RSV was reversed by proteasome inhibitors (MG-132 and lactacystin) and the ubiquitin inhibitor LDN57444, suggesting involvement of the ubiquitin-proteasome pathway. lactacystin 73-84 solute carrier family 10 member 2 Homo sapiens 0-4 24498857-7 2014 ASBT inhibition by RSV was reversed by proteasome inhibitors (MG-132 and lactacystin) and the ubiquitin inhibitor LDN57444, suggesting involvement of the ubiquitin-proteasome pathway. LDN 57444 114-122 solute carrier family 10 member 2 Homo sapiens 0-4 24498857-8 2014 Immunoprecipitation revealed high levels of ubiquitinated ASBT after RSV treatment. Resveratrol 69-72 solute carrier family 10 member 2 Homo sapiens 58-62 24498857-11 2014 Combined, our data indicate that RSV promotes ASBT degradation via the ubiquitin-proteasome pathway without requiring phosphorylation. Resveratrol 33-36 solute carrier family 10 member 2 Homo sapiens 46-50 24498857-12 2014 We conclude that regulation of ASBT expression by RSV may have clinical relevance with regard to the observed cholesterol-lowering effects of RSV. Resveratrol 50-53 solute carrier family 10 member 2 Homo sapiens 31-35 24498857-12 2014 We conclude that regulation of ASBT expression by RSV may have clinical relevance with regard to the observed cholesterol-lowering effects of RSV. Cholesterol 110-121 solute carrier family 10 member 2 Homo sapiens 31-35 24498857-12 2014 We conclude that regulation of ASBT expression by RSV may have clinical relevance with regard to the observed cholesterol-lowering effects of RSV. Resveratrol 142-145 solute carrier family 10 member 2 Homo sapiens 31-35 24045943-1 2013 Human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is responsible for intestinal reabsorption of bile acids and plays a key role in cholesterol homeostasis. Bile Acids and Salts 115-125 solute carrier family 10 member 2 Homo sapiens 53-58 24566561-4 2014 Bile acid based macromolecular substrates were synthesized and allowed to interact with ASBT. Bile Acids and Salts 0-9 solute carrier family 10 member 2 Homo sapiens 88-92 24566561-5 2014 ASBT/macromolecular substrate complexes were rapidly internalized in vesicles, localized in early endosomes, dissociated and escaped the vesicular transport while binding of cytoplasmic ileal bile acid binding proteins cause exocytosis of macromolecules and prevented entry into lysosomes. Bile Acids and Salts 192-201 solute carrier family 10 member 2 Homo sapiens 0-4 24328955-0 2014 Structural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids. Bile Acids and Salts 146-156 solute carrier family 10 member 2 Homo sapiens 77-82 24328955-8 2014 Glycine conjugates of native and isomeric BAs were subjected to molecular dynamics simulations to identify topological descriptors related to binding and translocation by hASBT. Glycine 0-7 solute carrier family 10 member 2 Homo sapiens 171-176 24328955-9 2014 Iso-BAs bound to hASBT with lower affinity and exhibited reduced translocation than their respective 3alpha-epimers. iso-bas 0-7 solute carrier family 10 member 2 Homo sapiens 17-22 23684867-16 2014 A lower amplitude of increase in O2Hb and decrease in HHb was found in the PFC in response to the CSBT with respect to the ISBT. csbt 98-102 solute carrier family 10 member 2 Homo sapiens 123-127 24196564-2 2014 SLC10A1 (sodium taurocholate cotransporting polypeptide [NTCP]) and SLC10A2 (apical sodium-dependent bile salt transporter [ASBT]) transport bile salts and play an important role in maintaining enterohepatic circulation of bile salts. Bile Acids and Salts 141-151 solute carrier family 10 member 2 Homo sapiens 68-75 24196564-2 2014 SLC10A1 (sodium taurocholate cotransporting polypeptide [NTCP]) and SLC10A2 (apical sodium-dependent bile salt transporter [ASBT]) transport bile salts and play an important role in maintaining enterohepatic circulation of bile salts. Bile Acids and Salts 141-151 solute carrier family 10 member 2 Homo sapiens 77-122 24196564-2 2014 SLC10A1 (sodium taurocholate cotransporting polypeptide [NTCP]) and SLC10A2 (apical sodium-dependent bile salt transporter [ASBT]) transport bile salts and play an important role in maintaining enterohepatic circulation of bile salts. Bile Acids and Salts 141-151 solute carrier family 10 member 2 Homo sapiens 124-128 24196564-2 2014 SLC10A1 (sodium taurocholate cotransporting polypeptide [NTCP]) and SLC10A2 (apical sodium-dependent bile salt transporter [ASBT]) transport bile salts and play an important role in maintaining enterohepatic circulation of bile salts. Bile Acids and Salts 223-233 solute carrier family 10 member 2 Homo sapiens 68-75 24196564-2 2014 SLC10A1 (sodium taurocholate cotransporting polypeptide [NTCP]) and SLC10A2 (apical sodium-dependent bile salt transporter [ASBT]) transport bile salts and play an important role in maintaining enterohepatic circulation of bile salts. Bile Acids and Salts 223-233 solute carrier family 10 member 2 Homo sapiens 77-122 24196564-2 2014 SLC10A1 (sodium taurocholate cotransporting polypeptide [NTCP]) and SLC10A2 (apical sodium-dependent bile salt transporter [ASBT]) transport bile salts and play an important role in maintaining enterohepatic circulation of bile salts. Bile Acids and Salts 223-233 solute carrier family 10 member 2 Homo sapiens 124-128 24196564-4 2014 However, ASBT has not been shown to be a transporter for non-bile salt substrates. Bile Acids and Salts 61-70 solute carrier family 10 member 2 Homo sapiens 9-13 24196564-6 2014 Transport of bile salts by NTCP and ASBT is inhibited by a number of drugs and it appears that ASBT is more permissive to drug inhibition than NTCP. Bile Acids and Salts 13-23 solute carrier family 10 member 2 Homo sapiens 36-40 24196564-6 2014 Transport of bile salts by NTCP and ASBT is inhibited by a number of drugs and it appears that ASBT is more permissive to drug inhibition than NTCP. Bile Acids and Salts 13-23 solute carrier family 10 member 2 Homo sapiens 95-99 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Bile Acids and Salts 168-178 solute carrier family 10 member 2 Homo sapiens 17-21 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Bile Acids and Salts 168-178 solute carrier family 10 member 2 Homo sapiens 139-143 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Bile Acids and Salts 168-177 solute carrier family 10 member 2 Homo sapiens 17-21 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Bile Acids and Salts 168-177 solute carrier family 10 member 2 Homo sapiens 139-143 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 17-21 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 139-143 24317697-6 2014 The crystal structure of an ASBT homologue from Neisseria meningitidis (ASBT(NM)) in detergent was reported recently, showing the protein in an inward-open conformation bound to two Na(+) and a taurocholic acid. Taurocholic Acid 194-210 solute carrier family 10 member 2 Homo sapiens 28-32 24317697-6 2014 The crystal structure of an ASBT homologue from Neisseria meningitidis (ASBT(NM)) in detergent was reported recently, showing the protein in an inward-open conformation bound to two Na(+) and a taurocholic acid. Taurocholic Acid 194-210 solute carrier family 10 member 2 Homo sapiens 72-76 24317697-8 2014 To understand the structural changes associated with the coupled transport of Na(+) and bile acids, here we solved two structures of an ASBT homologue from Yersinia frederiksenii (ASBTYf) in a lipid environment, which reveal that a large rigid-body rotation of a substrate-binding domain gives the conserved "crossover" region, where two discontinuous helices cross each other, alternating accessibility from either side of the cell membrane. Bile Acids and Salts 88-98 solute carrier family 10 member 2 Homo sapiens 136-140 24045943-1 2013 Human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is responsible for intestinal reabsorption of bile acids and plays a key role in cholesterol homeostasis. Bile Acids and Salts 115-125 solute carrier family 10 member 2 Homo sapiens 60-67 24045943-1 2013 Human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is responsible for intestinal reabsorption of bile acids and plays a key role in cholesterol homeostasis. Cholesterol 150-161 solute carrier family 10 member 2 Homo sapiens 53-58 24045943-1 2013 Human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is responsible for intestinal reabsorption of bile acids and plays a key role in cholesterol homeostasis. Cholesterol 150-161 solute carrier family 10 member 2 Homo sapiens 60-67 24045943-6 2013 Kinetic studies with conservative and non-conservative mutants of sodium sensitive residues further underscored the importance of Gln(75), Phe(76), Met(79), Gly(83), Leu(86), Phe(90), and Asp(91) in hASBT function. Sodium 66-72 solute carrier family 10 member 2 Homo sapiens 199-204 23815591-1 2013 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2), primarily expressed in the ileum, is involved in both the recycling of bile acids and cholesterol homeostasis. Bile Acids and Salts 145-155 solute carrier family 10 member 2 Homo sapiens 57-62 23815591-1 2013 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2), primarily expressed in the ileum, is involved in both the recycling of bile acids and cholesterol homeostasis. Bile Acids and Salts 145-155 solute carrier family 10 member 2 Homo sapiens 64-71 23815591-1 2013 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2), primarily expressed in the ileum, is involved in both the recycling of bile acids and cholesterol homeostasis. Cholesterol 160-171 solute carrier family 10 member 2 Homo sapiens 57-62 23815591-1 2013 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2), primarily expressed in the ileum, is involved in both the recycling of bile acids and cholesterol homeostasis. Cholesterol 160-171 solute carrier family 10 member 2 Homo sapiens 64-71 23687410-6 2013 The apical sodium-dependent bile acid transporter (ASBT) is expressed primarily in terminal ileum where it is a key factor for intestinal reabsorption of bile salts. Bile Acids and Salts 154-164 solute carrier family 10 member 2 Homo sapiens 51-55 23678871-1 2013 The apical sodium-dependent bile acid transporter (ASBT) transports bile salts from the lumen of the gastrointestinal (GI) tract to the liver via the portal vein. Bile Acids and Salts 68-78 solute carrier family 10 member 2 Homo sapiens 51-55 23678871-2 2013 Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. Cholesterol 97-108 solute carrier family 10 member 2 Homo sapiens 80-84 23678871-2 2013 Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. Cholesterol 97-108 solute carrier family 10 member 2 Homo sapiens 164-168 23678871-4 2013 We initiated a lead optimization effort that focused on the identification of a potent, nonabsorbable ASBT inhibitor starting from the first-generation inhibitor 264W94 (1). 264W 94 162-168 solute carrier family 10 member 2 Homo sapiens 102-106 23678871-5 2013 Extensive SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent, nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes. 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid 53-63 solute carrier family 10 member 2 Homo sapiens 103-107 23678871-5 2013 Extensive SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent, nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes. 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid 53-63 solute carrier family 10 member 2 Homo sapiens 291-295 23678871-5 2013 Extensive SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent, nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes. Glucose 131-138 solute carrier family 10 member 2 Homo sapiens 103-107 23752471-0 2013 Arylsulfonylamino-benzanilides as inhibitors of the apical sodium-dependent bile salt transporter (SLC10A2). arylsulfonylamino-benzanilides 0-30 solute carrier family 10 member 2 Homo sapiens 52-97 23752471-0 2013 Arylsulfonylamino-benzanilides as inhibitors of the apical sodium-dependent bile salt transporter (SLC10A2). arylsulfonylamino-benzanilides 0-30 solute carrier family 10 member 2 Homo sapiens 99-106 23752471-1 2013 The apical sodium-dependent bile salt transporter (ASBT) plays a pivotal role in maintaining bile acid homeostasis. Bile Acids and Salts 93-102 solute carrier family 10 member 2 Homo sapiens 4-49 23752471-1 2013 The apical sodium-dependent bile salt transporter (ASBT) plays a pivotal role in maintaining bile acid homeostasis. Bile Acids and Salts 93-102 solute carrier family 10 member 2 Homo sapiens 51-55 23752471-2 2013 Inhibition of ASBT would reduce bile acid pool size and lower cholesterol levels. Bile Acids and Salts 32-41 solute carrier family 10 member 2 Homo sapiens 14-18 23752471-2 2013 Inhibition of ASBT would reduce bile acid pool size and lower cholesterol levels. Cholesterol 62-73 solute carrier family 10 member 2 Homo sapiens 14-18 23752471-3 2013 In this report, a series of novel arylsulfonylaminobenzanilides were designed and synthesized as potential inhibitors of ASBT. arylsulfonylaminobenzanilides 34-63 solute carrier family 10 member 2 Homo sapiens 121-125 23752471-4 2013 Most of them demonstrated great potency against ASBT"s bile acid transport activity. Bile Acids and Salts 55-64 solute carrier family 10 member 2 Homo sapiens 48-52 23687410-9 2013 The alteration of the above-mentioned factors calls for attention: what is the relationship between CDXs and ASBT aberrant expression in BE? cdxs 100-104 solute carrier family 10 member 2 Homo sapiens 109-113 22853188-6 2012 Rietveld analysis of PXRD and SAED supported that both Pr and Ce ions are located on the 2a site in Pbam (space group no. Praseodymium 55-57 solute carrier family 10 member 2 Homo sapiens 100-104 23506869-9 2013 Finally, the newly found role of bile acids in glucose and energy homeostasis, via the TGR5 receptor, sheds new light on the clinical relevance of ASBT and NTCP. Bile Acids and Salts 33-43 solute carrier family 10 member 2 Homo sapiens 147-151 23319170-2 2013 METHODS: Target compound CA-lys-TFA was synthesized and tested for affinity toward the apical sodium dependent bile acid transporter (hASBT) and the Na+/taurocholate cotransporting polypeptide (hNTCP). ca-lys-tfa 25-35 solute carrier family 10 member 2 Homo sapiens 134-139 23319170-6 2013 RESULTS: CA-lys-TFA was a potent substrate of hASBT (Kt = 39.4 muM, normalized Vmax = 0.853) and hNTCP (Kt = 8.99 muM, normalized Vmax = 0.281). ca-lys-tfa 9-19 solute carrier family 10 member 2 Homo sapiens 46-51 22669917-1 2012 The apical Na(+)-dependent bile salt transporter (ASBT/SLC10A2) is essential for maintaining the enterohepatic circulation of bile salts. Bile Acids and Salts 126-136 solute carrier family 10 member 2 Homo sapiens 50-54 22354836-1 2012 PURPOSE: To explore the involvement of transmembrane domain (TM) 7 of the human apical sodium-dependent bile acid transporter (hASBT) on bile acid (BA) binding/translocation, using two electrophilic BA derivatives as molecular probes. Bile Acids and Salts 104-113 solute carrier family 10 member 2 Homo sapiens 127-132 22354836-1 2012 PURPOSE: To explore the involvement of transmembrane domain (TM) 7 of the human apical sodium-dependent bile acid transporter (hASBT) on bile acid (BA) binding/translocation, using two electrophilic BA derivatives as molecular probes. Bile Acids and Salts 148-150 solute carrier family 10 member 2 Homo sapiens 127-132 22354836-2 2012 METHODS: Two electrophilic derivatives of chenodeoxycholic acid (CDCA) were designed, synthesized and evaluated for their ability to inactivate hASBT, and the human organic cation/carnitine transporter (hOCTN2) as a control (i.e. a non-BA transporting model). Chenodeoxycholic Acid 42-63 solute carrier family 10 member 2 Homo sapiens 144-149 22354836-2 2012 METHODS: Two electrophilic derivatives of chenodeoxycholic acid (CDCA) were designed, synthesized and evaluated for their ability to inactivate hASBT, and the human organic cation/carnitine transporter (hOCTN2) as a control (i.e. a non-BA transporting model). Chenodeoxycholic Acid 65-69 solute carrier family 10 member 2 Homo sapiens 144-149 22354836-3 2012 The ability of electrophilic derivatives to interact with hASBT was evaluated by 2-aminoethyl-methanethiosulfonate (MTSEA)-biotin labeling of thiol groups in TM7 cysteine mutants. methanethiosulfonate ethylammonium 81-114 solute carrier family 10 member 2 Homo sapiens 58-63 22354836-3 2012 The ability of electrophilic derivatives to interact with hASBT was evaluated by 2-aminoethyl-methanethiosulfonate (MTSEA)-biotin labeling of thiol groups in TM7 cysteine mutants. methanethiosulfonate ethylammonium 116-121 solute carrier family 10 member 2 Homo sapiens 58-63 22354836-3 2012 The ability of electrophilic derivatives to interact with hASBT was evaluated by 2-aminoethyl-methanethiosulfonate (MTSEA)-biotin labeling of thiol groups in TM7 cysteine mutants. Biotin 123-129 solute carrier family 10 member 2 Homo sapiens 58-63 22354836-3 2012 The ability of electrophilic derivatives to interact with hASBT was evaluated by 2-aminoethyl-methanethiosulfonate (MTSEA)-biotin labeling of thiol groups in TM7 cysteine mutants. Sulfhydryl Compounds 142-147 solute carrier family 10 member 2 Homo sapiens 58-63 22354836-3 2012 The ability of electrophilic derivatives to interact with hASBT was evaluated by 2-aminoethyl-methanethiosulfonate (MTSEA)-biotin labeling of thiol groups in TM7 cysteine mutants. Cysteine 162-170 solute carrier family 10 member 2 Homo sapiens 58-63 22354836-4 2012 RESULTS: Unlike native BAs, the electrophilic CDCA derivatives specifically inactivated hASBT, but not hOCTN2, and inhibited hASBT in a time- and concentration-dependent fashion. Chenodeoxycholic Acid 46-50 solute carrier family 10 member 2 Homo sapiens 88-93 22354836-4 2012 RESULTS: Unlike native BAs, the electrophilic CDCA derivatives specifically inactivated hASBT, but not hOCTN2, and inhibited hASBT in a time- and concentration-dependent fashion. Chenodeoxycholic Acid 46-50 solute carrier family 10 member 2 Homo sapiens 125-130 22354836-5 2012 Preincubation of hASBT Cys-mutants in the exofacial half of TM7 with reactive electrophilic probes blocked transporter biotinylation by MTSEA-biotin, similar to 2-(trimethylammonium)ethyl-methanethiosulfonate (MTSET) blocking. N-biotinylaminoethyl methanethiosulfonate 136-148 solute carrier family 10 member 2 Homo sapiens 17-22 22354836-5 2012 Preincubation of hASBT Cys-mutants in the exofacial half of TM7 with reactive electrophilic probes blocked transporter biotinylation by MTSEA-biotin, similar to 2-(trimethylammonium)ethyl-methanethiosulfonate (MTSET) blocking. MTSET 210-215 solute carrier family 10 member 2 Homo sapiens 17-22 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. 5beta-bile alcohols 136-155 solute carrier family 10 member 2 Homo sapiens 70-74 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. 5beta-bile alcohols 136-155 solute carrier family 10 member 2 Homo sapiens 70-74 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. 5alpha- and 5beta-bile alcohols 229-260 solute carrier family 10 member 2 Homo sapiens 70-74 22669917-3 2012 We characterized ASBT orthologs from two primitive vertebrates, the lamprey that utilizes early 5alpha-bile alcohols and the skate that utilizes structurally different 5beta-bile alcohols, and compared substrate specificity with ASBT from humans who utilize modern 5beta-bile acids. 5alpha-bile alcohols 96-116 solute carrier family 10 member 2 Homo sapiens 17-21 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. 5alpha- and 5beta-bile alcohols 229-260 solute carrier family 10 member 2 Homo sapiens 70-74 22669917-3 2012 We characterized ASBT orthologs from two primitive vertebrates, the lamprey that utilizes early 5alpha-bile alcohols and the skate that utilizes structurally different 5beta-bile alcohols, and compared substrate specificity with ASBT from humans who utilize modern 5beta-bile acids. 5beta-bile alcohols 168-187 solute carrier family 10 member 2 Homo sapiens 17-21 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. Trichloroacetic Acid 282-285 solute carrier family 10 member 2 Homo sapiens 70-74 22669917-3 2012 We characterized ASBT orthologs from two primitive vertebrates, the lamprey that utilizes early 5alpha-bile alcohols and the skate that utilizes structurally different 5beta-bile alcohols, and compared substrate specificity with ASBT from humans who utilize modern 5beta-bile acids. 5beta-bile acids 265-281 solute carrier family 10 member 2 Homo sapiens 17-21 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. Trichloroacetic Acid 282-285 solute carrier family 10 member 2 Homo sapiens 70-74 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. 5alpha-bile alcohols 97-117 solute carrier family 10 member 2 Homo sapiens 70-74 22669917-7 2012 In contrast, human ASBT demonstrated high affinity for all three bile salt types. Bile Acids and Salts 65-74 solute carrier family 10 member 2 Homo sapiens 19-23 22669917-8 2012 These findings suggest that ASBT evolved from the earliest vertebrates by gaining affinity for modern bile salts while retaining affinity for older bile salts. Bile Acids and Salts 102-112 solute carrier family 10 member 2 Homo sapiens 28-32 22669917-8 2012 These findings suggest that ASBT evolved from the earliest vertebrates by gaining affinity for modern bile salts while retaining affinity for older bile salts. Bile Acids and Salts 148-158 solute carrier family 10 member 2 Homo sapiens 28-32 22669917-6 2012 Cell-based assays using recombinant ASBT/Asbt"s indicate that lamprey Asbt has high affinity for 5alpha-bile alcohols, low affinity for 5beta-bile alcohols, and lacks affinity for TCA, whereas skate Asbt showed high affinity for 5alpha- and 5beta-bile alcohols but low affinity for TCA. 5alpha-bile alcohols 97-117 solute carrier family 10 member 2 Homo sapiens 70-74 22403793-1 2012 Apical sodium-dependent bile acid transporter (ASBT) is responsible for the absorption of bile acids from the intestine. Bile Acids and Salts 90-100 solute carrier family 10 member 2 Homo sapiens 47-51 22403793-11 2012 Our studies provide novel evidence for the alterations in the activity of ASBT by EPEC infection and suggest a possible effect for EPEC in influencing intestinal bile acid homeostasis. Bile Acids and Salts 162-171 solute carrier family 10 member 2 Homo sapiens 74-78 22378771-8 2012 CGRP content was significantly decreased in capsaicin-treated IBAT demonstrating successful sensory nerve destruction. Capsaicin 44-53 solute carrier family 10 member 2 Homo sapiens 62-66 22378771-9 2012 T(IBAT) and T(c) were significantly decreased in capsaicin-treated hamsters compared with the saline controls at 2 h of cold exposure. Capsaicin 49-58 solute carrier family 10 member 2 Homo sapiens 0-7 21976025-0 2011 Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT. Bile Acids and Salts 50-59 solute carrier family 10 member 2 Homo sapiens 77-81 22016432-1 2012 The apical sodium-dependent bile acid transporter (ASBT) is expressed abundantly in the ileum and mediates bile acid absorption across the apical membranes. Bile Acids and Salts 28-37 solute carrier family 10 member 2 Homo sapiens 51-55 22016432-3 2012 Aberrant expression of both ASBT and CDXs in Barrett"s esophagus (BE) prompted us to study, whether the expression of the ASBT gene is regulated by CDXs. cdxs 148-152 solute carrier family 10 member 2 Homo sapiens 122-126 22016432-4 2012 Short interfering RNA-mediated knockdown of CDXs resulted in reduced ASBT mRNA expression in intestinal cells. cdxs 44-48 solute carrier family 10 member 2 Homo sapiens 69-73 22016432-5 2012 CDXs strongly induced the activity of the ASBT promoter in reporter assays in esophageal and intestinal cells. cdxs 0-4 solute carrier family 10 member 2 Homo sapiens 42-46 22016432-6 2012 Nine CDX binding sites were predicted in silico within the ASBT promoter, and binding of CDXs to six of them was verified in vitro and within living cells by electrophoretic mobility shift assays and chromatin immunoprecipitation assays, respectively. Cefadroxil 5-8 solute carrier family 10 member 2 Homo sapiens 59-63 22016432-6 2012 Nine CDX binding sites were predicted in silico within the ASBT promoter, and binding of CDXs to six of them was verified in vitro and within living cells by electrophoretic mobility shift assays and chromatin immunoprecipitation assays, respectively. cdxs 89-93 solute carrier family 10 member 2 Homo sapiens 59-63 23177985-2 2012 Although termed solute carriers (SLCs), only three out of seven (i.e. SLC10A1, SLC10A2, and SLC10A6) show sodium-dependent uptake of organic substrates across the cell membrane. Sodium 106-112 solute carrier family 10 member 2 Homo sapiens 79-86 22218036-0 2012 Altered bile acid pool using IBAT inhibitors for constipation: a potentially increased risk of malignancy. Bile Acids and Salts 8-17 solute carrier family 10 member 2 Homo sapiens 29-33 23177985-5 2012 The name "bile acid transporter family" arose because the first two SLC10 members (NTCP and ASBT) are carriers for bile salts that establish their enterohepatic circulation. Bile Acids and Salts 115-125 solute carrier family 10 member 2 Homo sapiens 92-96 22109685-2 2012 Bile acids are natural ligands for hASBT, but are hormones with high molecular weight, such that a recognition moiety that is not a bile acid may be advantageous. Bile Acids and Salts 0-10 solute carrier family 10 member 2 Homo sapiens 35-40 21649730-1 2011 BACKGROUND AND AIM: The major transporter responsible for bile acid uptake from the intestinal lumen is the apical sodium-dependent bile acid transporter (ASBT, SLC10A2). Bile Acids and Salts 58-67 solute carrier family 10 member 2 Homo sapiens 108-153 21649730-1 2011 BACKGROUND AND AIM: The major transporter responsible for bile acid uptake from the intestinal lumen is the apical sodium-dependent bile acid transporter (ASBT, SLC10A2). Bile Acids and Salts 58-67 solute carrier family 10 member 2 Homo sapiens 155-159 21649730-1 2011 BACKGROUND AND AIM: The major transporter responsible for bile acid uptake from the intestinal lumen is the apical sodium-dependent bile acid transporter (ASBT, SLC10A2). Bile Acids and Salts 58-67 solute carrier family 10 member 2 Homo sapiens 161-168 21649730-2 2011 Analysis of the SLC10A2 gene has identified a variety of sequence variants including coding region single nucleotide polymorphisms (SNPs) that may influence bile acid homeostasis/intestinal function. Bile Acids and Salts 157-166 solute carrier family 10 member 2 Homo sapiens 16-23 21649730-9 2011 A novel variant, 790A>G, was also shown to exhibit near complete loss of taurocholate transport, similar to the previously identified ASBT missense mutations. Taurocholic Acid 76-88 solute carrier family 10 member 2 Homo sapiens 137-141 21649730-12 2011 CONCLUSIONS: Genome sequencing and in vitro studies reveal the presence of multiple functionally relevant variants in SLC10A2 that may influence bile acid homeostasis and physiology. Bile Acids and Salts 145-154 solute carrier family 10 member 2 Homo sapiens 118-125 21976025-3 2011 However, bile acids released from the bile duct are constantly recycled, being reabsorbed in the intestine by the apical sodium-dependent bile acid transporter (ASBT, also known as SLC10A2). Bile Acids and Salts 9-19 solute carrier family 10 member 2 Homo sapiens 114-159 21976025-3 2011 However, bile acids released from the bile duct are constantly recycled, being reabsorbed in the intestine by the apical sodium-dependent bile acid transporter (ASBT, also known as SLC10A2). Bile Acids and Salts 9-19 solute carrier family 10 member 2 Homo sapiens 161-165 21976025-3 2011 However, bile acids released from the bile duct are constantly recycled, being reabsorbed in the intestine by the apical sodium-dependent bile acid transporter (ASBT, also known as SLC10A2). Bile Acids and Salts 9-19 solute carrier family 10 member 2 Homo sapiens 181-188 21976025-4 2011 It has been shown in animal models that plasma cholesterol levels are considerably lowered by specific inhibitors of ASBT, and ASBT is thus a target for hypercholesterolaemia drugs. Cholesterol 47-58 solute carrier family 10 member 2 Homo sapiens 117-121 21341987-1 2011 Genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP; SLC10A1) and ileal apical sodium-dependent bile acid transporter (ASBT; SLC10A2), which greatly contribute to bile acid homeostasis, were extensively explored in the Korean population and functional variants of NTCP were compared among Asian populations. Bile Acids and Salts 117-126 solute carrier family 10 member 2 Homo sapiens 140-144 21545606-0 2011 Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study. elobixibat 69-74 solute carrier family 10 member 2 Homo sapiens 31-58 21646357-1 2011 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) plays a critical role in the enterohepatic circulation of bile acids, as well as in cholesterol homeostasis. Bile Acids and Salts 131-141 solute carrier family 10 member 2 Homo sapiens 57-62 21646357-1 2011 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) plays a critical role in the enterohepatic circulation of bile acids, as well as in cholesterol homeostasis. Bile Acids and Salts 131-141 solute carrier family 10 member 2 Homo sapiens 64-71 21646357-1 2011 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) plays a critical role in the enterohepatic circulation of bile acids, as well as in cholesterol homeostasis. Cholesterol 157-168 solute carrier family 10 member 2 Homo sapiens 57-62 21646357-1 2011 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) plays a critical role in the enterohepatic circulation of bile acids, as well as in cholesterol homeostasis. Cholesterol 157-168 solute carrier family 10 member 2 Homo sapiens 64-71 21646357-2 2011 ASBT reclaims bile acids from the distal ileum via active sodium co-transport, in a multistep process, orchestrated by key residues in exofacial loop regions, as well as in membrane-spanning helices. Bile Acids and Salts 14-24 solute carrier family 10 member 2 Homo sapiens 0-4 21646357-2 2011 ASBT reclaims bile acids from the distal ileum via active sodium co-transport, in a multistep process, orchestrated by key residues in exofacial loop regions, as well as in membrane-spanning helices. Sodium 58-64 solute carrier family 10 member 2 Homo sapiens 0-4 21646357-5 2011 Cell surface expression of G50C and G50A was rescued upon MG132 treatment as well as cyclosporine A, but not by FK506 or bile acids, suggesting that Gly(50) is involved in hASBT folding. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 58-63 solute carrier family 10 member 2 Homo sapiens 172-177 21646357-5 2011 Cell surface expression of G50C and G50A was rescued upon MG132 treatment as well as cyclosporine A, but not by FK506 or bile acids, suggesting that Gly(50) is involved in hASBT folding. Cyclosporine 85-99 solute carrier family 10 member 2 Homo sapiens 172-177 21646357-5 2011 Cell surface expression of G50C and G50A was rescued upon MG132 treatment as well as cyclosporine A, but not by FK506 or bile acids, suggesting that Gly(50) is involved in hASBT folding. Glycine 149-152 solute carrier family 10 member 2 Homo sapiens 172-177 20968316-0 2010 Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid. Aminopyridines 62-75 solute carrier family 10 member 2 Homo sapiens 31-35 20848648-0 2011 Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). Gabapentin 37-47 solute carrier family 10 member 2 Homo sapiens 126-131 20848648-3 2011 The objective was to evaluate several bile acid conjugates of gabapentin as potential prodrugs that target hASBT. Bile Acids and Salts 38-47 solute carrier family 10 member 2 Homo sapiens 107-112 20848648-3 2011 The objective was to evaluate several bile acid conjugates of gabapentin as potential prodrugs that target hASBT. Gabapentin 62-72 solute carrier family 10 member 2 Homo sapiens 107-112 20848648-10 2011 These two conjugates are novel prodrugs of gabapentin and illustrate prodrugs that can be designed to target hASBT. Gabapentin 43-53 solute carrier family 10 member 2 Homo sapiens 109-114 20946088-6 2011 In contrast, NTCP*2 displayed greater transport of atorvastatin and rosuvastatin, compared with NTCP wild type. Atorvastatin 51-63 solute carrier family 10 member 2 Homo sapiens 13-19 20946088-6 2011 In contrast, NTCP*2 displayed greater transport of atorvastatin and rosuvastatin, compared with NTCP wild type. Rosuvastatin Calcium 68-80 solute carrier family 10 member 2 Homo sapiens 13-19 20946088-7 2011 Thus, the measurements of decreased rosuvastatin and atorvastatin transport by OATP1B1*15 were confounded by the presence of NTCP and its genetic variant, NTCP*2. Rosuvastatin Calcium 36-48 solute carrier family 10 member 2 Homo sapiens 155-161 20946088-7 2011 Thus, the measurements of decreased rosuvastatin and atorvastatin transport by OATP1B1*15 were confounded by the presence of NTCP and its genetic variant, NTCP*2. Atorvastatin 53-65 solute carrier family 10 member 2 Homo sapiens 155-161 21090654-3 2010 An indolenine intermediate is implicated in the addition step, and surprisingly, water cosolvent was found to have a beneficial effect in this step, leading to a one-pot protocol for elimination/enantioselective addition using PBAM, a bis(amidine) chiral nonracemic base. indolenine 3-13 solute carrier family 10 member 2 Homo sapiens 227-231 21090654-3 2010 An indolenine intermediate is implicated in the addition step, and surprisingly, water cosolvent was found to have a beneficial effect in this step, leading to a one-pot protocol for elimination/enantioselective addition using PBAM, a bis(amidine) chiral nonracemic base. Water 81-86 solute carrier family 10 member 2 Homo sapiens 227-231 20066493-1 2011 The apical sodium-codependent bile acid transporter (ASBT) inhibition activity of benzothiepine derivatives have been analyzed based on topological and molecular features. 1-Benzothiepin 82-95 solute carrier family 10 member 2 Homo sapiens 53-57 21103970-4 2011 The ileal apical sodium-dependent bile acid cotransporter (abbreviated ASBT; gene symbol, SLC10A2) is responsible for the initial uptake of bile acids across the enterocyte brush border membrane. Bile Acids and Salts 140-150 solute carrier family 10 member 2 Homo sapiens 71-75 21103970-4 2011 The ileal apical sodium-dependent bile acid cotransporter (abbreviated ASBT; gene symbol, SLC10A2) is responsible for the initial uptake of bile acids across the enterocyte brush border membrane. Bile Acids and Salts 140-150 solute carrier family 10 member 2 Homo sapiens 90-97 20939504-1 2010 The human apical sodium dependent bile acid transporter (hASBT) reabsorbs gram quantities of bile acid daily and is a potential prodrug target to increase oral drug absorption. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 57-62 20939504-3 2010 The objective was to derive a conformationally sampled pharmacophore 3D-QSAR (CSP-SAR) model for the uptake of bile acid conjugates by hASBT. Bile Acids and Salts 111-120 solute carrier family 10 member 2 Homo sapiens 135-140 20939504-4 2010 A series of bile acid conjugates of glutamyl chenodeoxycholate were evaluated in terms of K(m) and normalized V(max) (normV(max)) using hASBT-MDCK cells. Bile Acids and Salts 12-21 solute carrier family 10 member 2 Homo sapiens 136-141 20939504-4 2010 A series of bile acid conjugates of glutamyl chenodeoxycholate were evaluated in terms of K(m) and normalized V(max) (normV(max)) using hASBT-MDCK cells. glutamyl chenodeoxycholate 36-62 solute carrier family 10 member 2 Homo sapiens 136-141 20968316-0 2010 Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid. Chenodeoxycholic Acid 90-111 solute carrier family 10 member 2 Homo sapiens 31-35 20968316-3 2010 A series of 27 aminopyridine and aminophenol conjugates of glutamyl-chenodeoxycholate were synthesized and their ASBT inhibition and transport kinetics (parametrized as K(i), K(t), and J(max)) measured using stably transfected ASBT-MDCK cells. glutamyl-chenodeoxycholate 59-85 solute carrier family 10 member 2 Homo sapiens 113-117 20968316-11 2010 Overall, steric and hydrophobic features around the 24 position of the sterol nucleus strongly influenced bile acid conjugate interaction with ASBT. Sterols 71-77 solute carrier family 10 member 2 Homo sapiens 143-147 20968316-11 2010 Overall, steric and hydrophobic features around the 24 position of the sterol nucleus strongly influenced bile acid conjugate interaction with ASBT. Bile Acids and Salts 106-115 solute carrier family 10 member 2 Homo sapiens 143-147 21231006-2 2010 State-of-the-art calculations (maximum entropy method) reveal that (CuCl)LaNb2O7 is orthorhombic with Pbam symmetry. (cucl)lanb2o7 67-80 solute carrier family 10 member 2 Homo sapiens 102-106 20504026-2 2010 Synthetic, biological, NMR, and computational approaches identified the structure-activity relationships of mono- and dianionic bile acid conjugates for hASBT binding. mono- and dianionic bile acid 108-137 solute carrier family 10 member 2 Homo sapiens 153-158 20600720-1 2010 The objective was to synthesize prodrugs of niacin and ketoprofen that target the human apical sodium-dependent bile acid transporter (ASBT) and potentially allow for prolonged drug release. Niacin 44-50 solute carrier family 10 member 2 Homo sapiens 88-133 20600720-1 2010 The objective was to synthesize prodrugs of niacin and ketoprofen that target the human apical sodium-dependent bile acid transporter (ASBT) and potentially allow for prolonged drug release. Niacin 44-50 solute carrier family 10 member 2 Homo sapiens 135-139 20600720-1 2010 The objective was to synthesize prodrugs of niacin and ketoprofen that target the human apical sodium-dependent bile acid transporter (ASBT) and potentially allow for prolonged drug release. Ketoprofen 55-65 solute carrier family 10 member 2 Homo sapiens 88-133 20600720-1 2010 The objective was to synthesize prodrugs of niacin and ketoprofen that target the human apical sodium-dependent bile acid transporter (ASBT) and potentially allow for prolonged drug release. Ketoprofen 55-65 solute carrier family 10 member 2 Homo sapiens 135-139 20600720-10 2010 In vitro results showed that these bile acid conjugates are potential prolonged release prodrugs with binding affinity for ASBT. Bile Acids and Salts 35-44 solute carrier family 10 member 2 Homo sapiens 123-127 20548267-10 2010 In the CP-12h group, the ratios of the ASBT/ILBP, ASBT/Ostalpha and ASBT/Ostbeta expression levels were correlated with the injury severity scores of large but not small bile ducts. cp-12h 7-13 solute carrier family 10 member 2 Homo sapiens 39-43 20548267-10 2010 In the CP-12h group, the ratios of the ASBT/ILBP, ASBT/Ostalpha and ASBT/Ostbeta expression levels were correlated with the injury severity scores of large but not small bile ducts. cp-12h 7-13 solute carrier family 10 member 2 Homo sapiens 50-54 20548267-10 2010 In the CP-12h group, the ratios of the ASBT/ILBP, ASBT/Ostalpha and ASBT/Ostbeta expression levels were correlated with the injury severity scores of large but not small bile ducts. cp-12h 7-13 solute carrier family 10 member 2 Homo sapiens 50-54 20056894-0 2010 Green tea catechin EGCG inhibits ileal apical sodium bile acid transporter ASBT. Catechin 10-18 solute carrier family 10 member 2 Homo sapiens 75-79 20056894-0 2010 Green tea catechin EGCG inhibits ileal apical sodium bile acid transporter ASBT. epigallocatechin gallate 19-23 solute carrier family 10 member 2 Homo sapiens 75-79 20056894-2 2010 Ileal apical sodium-dependent bile acid transporter (ASBT) is responsible for reabsorption of bile acids. Bile Acids and Salts 94-104 solute carrier family 10 member 2 Homo sapiens 53-57 20056894-3 2010 The present studies were, therefore, designed to investigate the modulation of ASBT function and membrane expression by green tea catechins in human embryonic kidney HEK-293 cells stably transfected with ASBT-V5 fusion protein and intestinal Caco-2 monolayers. Catechin 130-139 solute carrier family 10 member 2 Homo sapiens 79-83 20056894-4 2010 Our data showed that ASBT activity was significantly decreased by (-)-epigallocatechin-3-gallate (EGCG) but not other green tea catechins. epigallocatechin gallate 66-96 solute carrier family 10 member 2 Homo sapiens 21-25 20056894-4 2010 Our data showed that ASBT activity was significantly decreased by (-)-epigallocatechin-3-gallate (EGCG) but not other green tea catechins. epigallocatechin gallate 98-102 solute carrier family 10 member 2 Homo sapiens 21-25 20056894-7 2010 Concomitant with the decrease in ASBT function, EGCG significantly reduced ASBT pool in the detergent-insoluble fraction, while increasing its presence in the detergent-soluble fraction of plasma membrane. epigallocatechin gallate 48-52 solute carrier family 10 member 2 Homo sapiens 75-79 20056894-8 2010 Furthermore, EGCG decreased the association of ASBT with floating lipid raft fractions of cellular membrane on Optiprep density gradient. epigallocatechin gallate 13-17 solute carrier family 10 member 2 Homo sapiens 47-51 20056894-9 2010 In conclusion, our data demonstrate a novel role of lipid rafts in the modulation of ASBT function by the dietary component EGCG, which may underlie the hypocholesterolemic effects of green tea. epigallocatechin gallate 124-128 solute carrier family 10 member 2 Homo sapiens 85-89 19643091-8 2009 MSG- and vehicle-treated hamsters given an exogenous norepinephrine challenge showed identical increases in the duration and peak of T(IBAT). Norepinephrine 53-67 solute carrier family 10 member 2 Homo sapiens 135-139 19673539-1 2009 The human apical sodium-dependent bile acid transporter (ASBT; SLC10A2) is the primary mechanism for intestinal bile acid reabsorption. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 57-61 19653651-2 2009 Sequence alignment of SLC10 family members has previously identified a signature motif (ALGMMPL) localized to TM3 of ASBT with as yet undetermined function. algmmpl 88-95 solute carrier family 10 member 2 Homo sapiens 117-121 19653651-4 2009 Additional conservative and nonconservative replacement of P142 suggests its structural and functional importance during the ASBT transport cycle. 1,1-Diphenylhydrazine hydrochloride 59-63 solute carrier family 10 member 2 Homo sapiens 125-129 19571234-0 2009 Modulation of ileal apical Na+-dependent bile acid transporter ASBT by protein kinase C. Ileal apical Na(+)-dependent bile acid transporter (ASBT) is responsible for reabsorbing the majority of bile acids from the intestinal lumen. Bile Acids and Salts 194-204 solute carrier family 10 member 2 Homo sapiens 63-67 19571234-0 2009 Modulation of ileal apical Na+-dependent bile acid transporter ASBT by protein kinase C. Ileal apical Na(+)-dependent bile acid transporter (ASBT) is responsible for reabsorbing the majority of bile acids from the intestinal lumen. Bile Acids and Salts 194-204 solute carrier family 10 member 2 Homo sapiens 141-145 19571234-1 2009 Rapid adaptation of ASBT function in response to physiological and pathophysiological stimuli is essential for the maintenance of bile acid homeostasis. Bile Acids and Salts 130-139 solute carrier family 10 member 2 Homo sapiens 20-24 19571234-4 2009 The present studies were, therefore, undertaken to investigate ASBT regulation in intestinal Caco-2 monolayers by the well-known PKC activator phorbol 12-myristate 13-acetate (PMA). Tetradecanoylphorbol Acetate 143-174 solute carrier family 10 member 2 Homo sapiens 63-67 19571234-4 2009 The present studies were, therefore, undertaken to investigate ASBT regulation in intestinal Caco-2 monolayers by the well-known PKC activator phorbol 12-myristate 13-acetate (PMA). Tetradecanoylphorbol Acetate 176-179 solute carrier family 10 member 2 Homo sapiens 63-67 19571234-9 2009 Our novel findings demonstrate a posttranscriptional modulation of ileal ASBT function and membrane expression by phorbol ester via a PKCzeta-dependent pathway. Phorbol Esters 114-127 solute carrier family 10 member 2 Homo sapiens 73-77 19673539-1 2009 The human apical sodium-dependent bile acid transporter (ASBT; SLC10A2) is the primary mechanism for intestinal bile acid reabsorption. Bile Acids and Salts 34-43 solute carrier family 10 member 2 Homo sapiens 63-70 19174784-4 2009 Several bile acid transporters are utilized for effective removal of bile acids, including the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP), and the multidrug-resistant protein 3 (MRP3). Bile Acids and Salts 69-79 solute carrier family 10 member 2 Homo sapiens 95-140 19384469-0 2009 Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. N-aminopiperidine 97-112 solute carrier family 10 member 2 Homo sapiens 84-89 19384469-0 2009 Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. glutamyl-bile acids 127-146 solute carrier family 10 member 2 Homo sapiens 84-89 19384469-1 2009 PURPOSE: Synthesize aminopiperidine conjugates of glutamyl-bile acids (glu-BAs) and develop a hASBT inhibition model using the conformationally sampled pharmacophore (CSP) approach. glutamyl-bile acids 50-69 solute carrier family 10 member 2 Homo sapiens 94-99 19384469-14 2009 CONCLUSIONS: Aminopiperidine conjugates of glu-BAs were potent hASBT inhibitors. N-aminopiperidine 13-28 solute carrier family 10 member 2 Homo sapiens 63-68 19184108-1 2009 The apical sodium-dependent bile acid transporter (SLC10A2) plays a key role in the reabsorption of luminal bile acids into the enterohepatic circulation. Bile Acids and Salts 108-118 solute carrier family 10 member 2 Homo sapiens 51-58 19184108-2 2009 Rare variations in SLC10A2 have been reported to be associated with Crohn"s disease, primary bile acid malabsorption and familial hypertriglyceridemia; however, variants associated with reduced SLC10A2 expression have not been reported to date. Bile Acids and Salts 93-102 solute carrier family 10 member 2 Homo sapiens 19-26 19174784-4 2009 Several bile acid transporters are utilized for effective removal of bile acids, including the apical sodium-dependent bile acid transporter (ASBT), the ileal bile acid-binding protein (IBABP), and the multidrug-resistant protein 3 (MRP3). Bile Acids and Salts 69-79 solute carrier family 10 member 2 Homo sapiens 142-146